Istitution of Page Charges
Effective January 1, 1998, a page charge of $50 per printed page will be levied on all manuscripts published in Clinical Cancer Research. This page charge is intended to cover the cost of publication. Under exceptional circumstances, when no other source of support exists, the author(s) may apply to Dr. Margaret Foti, Director of Publications, AACR Publications Department (see page ii for address) at the time of submission for a waiver of the page charges. All such applications must be counter signed by an appropriate institutional official stating that no funds are available for the payment of page charges.

1999 Annual Meeting
The AACR’s Annual Meeting is one of the largest and most important annual gatherings of scientists engaged in cancer research worldwide. The next Annual Meeting will take place in Philadelphia, PA, April 10–14, 1999. The Chairperson of the Annual Meeting is Waun Ki Hong of the UT-M.D. Anderson Cancer Center. Co-Chairpersons are Carol W. Greider, John Hopkins University School of Medicine; Joseph F. Fraumeni, Jr., National Cancer Institute; and Leroy Fong Liu, Robert Wood Johnson Medical School.

The Program Committee will invite outstanding scientists in the field to organize plenary sessions, symposia, scientific workshops or expert seminar sessions. It will also review proffered papers submitted by members of the cancer research community and will schedule acceptable ones in mini-symposia, posters and discussion sessions. The deadline for submission of abstracts will be November 6, 1998. Further program information can be found on the AACR’s Website (http://www.aacr.org).

Call for Nominations for 1999 AACR-Pezzler International Award for Cancer Research
The AACR-Pezzler International Award for Cancer Research is given annually to a scientist who has made a major contribution in the field of cancer, who continues to be active in the field, and whose ongoing work will be recognized through future contributions to cancer research. The Pezzer Foundation was established in 1982 by Professor Alessio Pezzer, a dedicated Italian surgeon who has made important contributions to medicine during his career and who, through his foresight, vision, and generous gift in support of the Foundation’s mission, stimulated others to make significant advances in cancer research. Over the past decade the Pezzer Foundation has given a major award to several outstanding contributions to cancer and cancer-related biomedical science.

The American Association for Cancer Research (AACR) established in 1907 by eleven physicians and scientists dedicated to the conquest of cancer and now has over 13,000 members in more than 60 countries who are expounding and broadening public understanding and knowledge of cancer research. The AACR fulfills its mission in a variety of forums, including publications, meetings, and training and education. The AACR has submitted for the first time the online version of the AACR Bulletin to the American Association for Cancer Research (AACR) as a platform for dissemination of the AACR Bulletin. The AACR Bulletin is a publication of the American Association for Cancer Research (AACR). The AACR Bulletin is published six times a year, beginning with the first issue in March 1999. The AACR Bulletin is published by the AACR, a nonprofit organization. The AACR Bulletin is available for free online at the AACR’s website (http://www.aacr.org). The AACR Bulletin is indexed in PubMed and is included in the PubMed Central repository. The AACR Bulletin is also available for purchase at the AACR website (http://www.aacr.org). The AACR Bulletin is distributed to members and non-members of the AACR, and it is available for free online at the AACR’s website (http://www.aacr.org). The AACR Bulletin is distributed to members and non-members of the AACR, and it is available for free online at the AACR’s website (http://www.aacr.org).
AUTHOR INDEX

December 1998

Abbuzese, J. L., 3069
Adato, P., 3031
Ahmadian, M., 2931
Amane, M., 3077
Amemiya, A., 2985
Anzick, S., 2925
Appelbaum, F. R., 3051
Ashfaq, R., 2931
Au, J. L.-S., 2949
Bander, N. H., 2957
Banker, D. E., 3051
Barrett, J. C., 3005
Bautista, S., 2925
Becker, A., 3051
Behrens, C., 2931
Berchuck, A., 3005
Bianco, F. J., Jr., 3011
Blankaert, V. D., 2939
Bondy, M. L., 3031
Bruner, J. L., 3031
Butler, J., 3083
Carney, M. E., 3005
Chang, K.-T., 3025
Chen, J.-Y., 3025
Chia, N.-C., 2967
Chinchilli, V., 3037
Choi, J.-Y., 3063
Colbern, G. T., 3077
Crissman, J. D., 3011
Cunningham, T. H., 2931
Curley, E. 3037
Danks, M. K., 3089
Dobashi, K., 2999
Dodge, R. K., 3005
Dykes, D. J., 3077
Engbers, C., 3077
Farr, W.-H., 2967
Feldman, M., 2957
Ferrandina, G., 3069
Fink, U., 2991
Freedman, R. S., 3069
Fridman, R., 3011
Fu, H.-T., 3025
Gabbert, H. E., 2991
Gan, Y., 2949
Gatter, K. C., 3017
Gazdar, A. F., 2931
Georgoulas, V., 3017
Gervasi, D. C., 3011
Giatromanolaki, A., 3017
Grignon, D. J., 3011
Gu, J., 3031
Guichard, S. M., 3089
Hamajima, N., 2999
Hargreaves, R. H. J., 3083
Harris, A. L., 3017
Hayes, K., 3005
Hebbar, M., 2939
Hess, K. R., 3031
Hicklin, D. J., 2957
Hiller, A., 3077
Holcmenberg, J. S., 2981
Hum, M., 2981
Ishiwata, I., 2985
Iwamori, M., 2985
Kakolyris, S., 3017
Kamen, B. A., 2981
Kang, Y.-K., 3063
Kerkof, K., 3051
Kidouchi, K., 2999
Kiguchi, K., 2985
Kim, C. S., 3063
Kim, J. S., 3063
Kim, Y. H., 3063
Koukourakis, M. I., 3017
Kouwaki, M., 2999
Krull, E. J., 3089
Kuo, B. I.-T., 3025
Kurvari, V., 2931
Kyritsis, A. P., 3031
Lai, C.-L., 3025
Lee, J.-H., 3045
Lee, K.-H., 3063
Leitzel, K., 3037
Levin, V. A., 3031
Lie, B., 3037
Lipton, A., 3037
Loercher, A., 3069
Louchez, M.-M., 2939
Luzzio, M., 3077
Maxwell, G. L., 3005
McMillan, D. C., 2977
Melichar, B., 3069
Meltzer, P., 2925
Milkgrub, S., 2931
Minnia, J. D., 2931
Morton, C. L., 3089
Mürekköster, S., 3095
Musterer, R., 3077
Narla, R.-K., 2967
Nonaka, M., 2999
Norwood, T., 3051
O’Byrne, K., 3017
Park, J. K., 3063
Pegg, E., 3077
Perng, R.-P., 3025
Peyrat, J.-P., 2939
Pezzella, F., 3017
Pontes, J. E., 3011
Potter, P. M., 3089
Prewett, M., 2957
Radich, J., 3051
Rhee, C. H., 3045
Risinger, J. I., 3005
Rocha, M., 3095
Ross, D., 3083
Rothman, M., 2957
Rychlik, W., 3037
Saka, M., 2985
Sarbia, M., 2991
Sasaki, M., 2999
Sattar, N., 2977
Saville, R., 3077
Schelling, M. E., 2939
Schirmacher, V., 3095
Scott, P. A. E., 3017
Seeber, S., 2991
Shim, C., 3045
Shin, S. W., 3063
Sigurdson, A. J., 3031
Smith, J., 3037
Stahl, M., 2991
Stewart, C. F., 3089
Sumit, S., 2999
Syed, S., 2931
Theillet, C., 2925
Tigges, R., 3011
Tkaczykowski, L., 2981
Togari, H., 2999
Toms, S. A., 3031
Tsai, C.-M., 3025
Tsai, T.-T., 3025
Turley, H., 3017
Uckun, F. M., 2967
Umansky, V., 3095
Uster, P., 3077
Vallés, H., 2925
Verschraegen, C. F., 3069
Vilain, M.-O., 2939
Virmaci, A. K., 2931
Wachowski, O., 3095
Wada, Y., 2999
Wakasal, H., 2957
Walker, R. L., 2925
Wallace, A. M., 2977
Wang, L.-E., 3031
Wang, X., 3031
Weaver, J. W., 2981
Wei, Q., 3031
Weng, S., 3077
Wientjes, M. G., 2949
Willers, R., 2991
Willman, C. M., 3051
Wilson, J., 2981
Winski, S. L., 3083
Wistuba, I. L., 2931
Wood, D. P., Jr., 3011
Working, P. K., 3077
Yamamoto, S., 2985
Yoo, Y. D., 3063
Yung, W. K. A., 3031
Zeillinger, R., 2925
Zerban, H., 3095
Zhang, W., 3045
Zhu, D.-M., 2967
Acknowledgment to Reviewers

The Editor-in-Chief, Deputy Editor, and Senior Editors acknowledge with appreciation the assistance of the following individuals who have generously contributed their time and effort during the past year* to review manuscripts for Clinical Cancer Research. The quality of the journal can be attributed in large measure to the quality of their effort, for which we are sincerely grateful.

A

Andrea Abati
James L. Abbruzzese
Abraham Abuchockis
Alex A. Adjei
Bharat B. Aggarwal
Steven Ahrendt
Moulay A. Alaoui-Jamali
Rima Al-Awar
Anthony P. Albino
Maher Albitar
Raymond Alexander
Iqbal A. Ali
Francis Ali-Osman
Carmen J. Allegra
Enrique Alvarez
Jim Amatrudà
Matthew M. Ames
Ian C. Anderson
Kenneth C. Anderson
Wayne B. Anderson
Kie-Kian Ang
Phillipe G. Anker
Frederick R. Appelbaum
Gulshan Ara
Robert J. Arceci
Bradley A. Arrick
Carlos L. Arteaga
Robert Auerbach
Leonard H. Augerli
Sadie A. Aznavoorian

B

Silvia Bacchetti
Howard H. Bailey
Carl G. Baker
Frank M. Balis
Douglas W. Ball
Marcel B. Bally
Mary Helen Barcellos-Hoff
Diana M. Barnes
Rolf F. Barth
José Baselga
Robert C. Bast, Jr.
Alakananda Basu
Tracy Batchelor
Susan E. Bates
Hector Battifora
J. David Beatty
William T. Beck
Richard Beckman
Gauri C. Bedi
Arie S. Belledegrun
William F. Benedict
Ralph J. Bernacki
Steven E. Benner
William P. Bennett
Andrew Berchuck
David A. Berd
Jonas C. S. Bergh
Jordan D. Berlin
Ellin Berman
Joseph R. Bertino
Darel D. Bigner
Michael J. Birrer
Alan J. Bittardi
Jacob D. Bitran
Georg Bjarnason
Janet D. Black
Saban Bilenidi
C. Richard Boland
Reinder L. H. Bolhuis
Benjamin Bonavida
Charles W. Boone
David A. Boothman
Anthony Boral
Ernest C. Borden
Paul Bornstein
Franz X. Bosch
George J. Bosl
Anja-Katrin Bosserhoff
Klaus Bosslet
Jeffrey A. Boyd
Ruud H. Brakenhoff
Elisabeth M. P. Brambilla
Steven R. Brant
Henry Brem
Rachel F. Brem
Malcolm Brenner
Thomas P. Brent
Robert S. Bresalier
Tim Browder
Carol Brown
J. Martin Brown
Lawrence Brown
Monica Brown
Myles A. Brown
Powel Brown
Michael J. Brunda
Nils Brünger
Aby Buchbinder
Reinhard Buettner
Alberto Bugliolo
Ronald M. Bukowski
Joan Marie Bull
Edward A. Bump
Paul A. Bunn, Jr.
William J. Burslem
Howard Burstein
Aman U. Buzdar
Fernando Cabanillas
Paul Calabresi
David Callender
Barbara G. Campling
Paul Cairns
Stephen A. Cannistra
Robert L. Capizzi
David Paul Carbone
Michael A. Carducci
Lisa A. Carey
Thomas E. Carey
Robert W. Carlson
Ephraim S. Casper
Alan G. Casson
Vincent Castronovo
Webster K. Cavenee
Kenneth K. Chan
Alfred E. Chang
Esther H. Chang
Dai Chaplin
Paul B. Chapman
Marcio Chedid
Martin A. Cheever
Victor Chen
Michael L. Cher
Nino Chiocca
Kathleen R. Cho
Yoon Sang Cho-Chung
Noah C. Choi
Jia-Ling Chou
Hak Choy
Edward Chu
Leland W. K. Chung
Margie Lee Clapper
Gary M. Clark
Robert Clarke
Gary L. Clayman
Karen R. Cleary
Steven K. Clinton
Jeffery A. Coderre
Justin Cohen
Thomas V. Colby
C. Norman Cole
Jerry M. Collins
Carson Clifford Conaway
Barbara Conley
Claudio J. Conti
John Contois
David L. Cooper
Carlos Cordon-Cardo
Peter M. Corry
Euge C. Cortes
Jose Costa
Richard Cote
Kenneth H. Cowan
Timothy Cripe
Ronald G. Crystal
Kevin J. Cullen
Bogdan Czezniak

D

William S. Dalton
Donna Neuberg Dana
Peter V. Danenberg
Mary K. Danks
Anne H. Dantzig
Gokul C. Das
Nancy E. Davidson
Faith G. Davis
Marcia I. Dawson
Nooribhi K. Day
Elizabeth Dean-Clower
Larisa V. Debelenko
Yves A. De Clercq
Hadasa Degani
Farrokh Dehdashti
Albert B. Deisseroth
Thomas F. Delaney
Marc E. DelClos
David T. Denhardt
Russell F. Devore
Kapil Dhingra
Robert B. Diasio
Robert O. Dillman
Maurizio D'Incalci
Colin P. Dinney
Ethan Dmitrovsky
M. Eileen Dolan
Bruce J. Dolnick
James H. Doroshow
Robert T. Dorr
Thomas J. Dougherty
Glenn Dranoff
Louis Dubeau
Raymond N. Dubois
Paul H. Duray
Janice P. Dutcher

E

H. Shelton Earp, III
Alan R. Eastman
David J. Easty
S. Gail Eckhardt
Joseph Paul Edel
Merrill J. Egorin
Leah Eisenbach
Mario A. Eisenberger
Anthony D. Elias

*October 1, 1997–September 30, 1998
Wheless, L. L., 1267
White, L., 595
White, S. A., 2903
Whitehead, V. M., 183
Whiteside, T. L., 1135
Wibborny, D., 2047
Wiemann, T. J., 2741
Wientjes, M. G., 139, 277, 2949
Wiersma, S., 45
Wilding, G., 1159, 1429
Willkerson, C. L., 2253
Wilks, D. P., 2795
Willke, F., 343, 1779
Willers, R., 577, 2615, 2991
Williams, J. M., 2729
Williams, L., 2511
Williamson, M., 2169
Willman, C., 3051
 Willis, K. N., 1649
Wilson, J., 2981
Winski, S. L., 3083
Winter, M. R., 2787
Wirtz, H-C., 1749
Wissel, P., 957
Wisitub, I. I., 2931
Wloch, M., 879
Wolfe, J. D., 869
Wong, S. C., 2169
Wood, D. P., Jr., 2119, 3011
Woodcock, D. M., 2321
Woodruff, J. M., 2377
Woodworth, J. R., 605
Working, P. K., 111, 3077
Wright, S. R., 2279
Wu, X., 2447
Wuest, D., 311
Wullich, B., 197
Wurtz, A., 1375
X
Xiang, R., 2551
Xiao, L., 2003
Xiong, Y. P., 1227
Xu, F. J., 2545
Xu, G., 317
Xu, H-J., 1955
Xu, J., 861
Xu, Y., 171
Xu, Y-Z., 1719
Y
Yagita, H., 713
Yakulis, R., 913
Yakushiji, M., 235
Yamada, T., 1527
Yamada, Y., 1619
Yamaguchi, Y., 1147
Yamanouchi, S., 2985
Yamao, T., 1469
Yamashita, K., 2771
Yamazaki, H., 1785
Yan, Y., 2859
Yang, D., 993, 1005
Yang, G., 1873
Yang, J., 215
Yang, J-M., 1393
Yang, L., 731, 1005
Yang, S-C., 555
Yanishevsky, Y., 165, 1125
Yao, J., 1065
Yashima, K., 229
Yayoi, E., 177
Yeatman, T. J., 879
Yee, L., 1165
Yeh, I. T., 2577
Yenrudi, S., 665
Yeung, H. W., 1765
Yoe, J., 1437
Yogita, S., 1475
Yonezawa, S., 2605
Yoo, Y. D., 3063
Yoon, S. K., 1711
Yoshida, K., 2195
Yoshida, S., 1469
Yoshikawa, K., 31
Yoshikubo, T., 1013
Yoshinouchi, M., 979
Yu, D., 1065, 1573, 1985
Yu, G., 1177
Yu, H., 1489
Yu, R., 1631
Yung, W. K. A., 2447, 3031
Z
Zabalegui, A., 1679
Zaber, A., 869
Zahurak, M., 21
Zahurak, M. L., 349
Zalczman, G., 1359
Zalutsky, M. R., 2071, 2495
Zamboni, W. C., 455, 743, 783, 2537
Zaninelli, M., 2331
Zanzi, L., 61
Zeillinger, R., 2925
Zelenetz, A. D., 311
Zelenisch-Jacquotte, A., 545
Zellner, A., 1797
Zerban, H., 3095
Zeren, T., 165, 901, 1125
Zhang, H. S., 295, 2669
Zhang, L., 697, 2169
Zhang, R., 325
Zhang, S., 295, 2669
Zhang, W., 1251, 3045
Zhang, Z. F., 419
Zhao, Y., 567
Zheng, Y., 2657
Zhong, G. R., 2483
Zhou, J., 1631
Zhou, L., 1227
Zhou, X., 1865
Zhu, D-M., 2967
Zhu, S. J., 2877
Zhuang, Z., 1673
Zi, X., 1055
Zielinski, Z. 469
Zietman, A., 2787
Zimmermann, K., 2615
Zonis, S., 389
Zou, C-C., 1345
Zou, C-P., 1345
Zu, Z., 2717
Zuna, I., 2305
Zunino, F., 262, 2833
Zur Hausen, A., 2615
Zwerger, T., 197
SUBJECT INDEX

Volume 4

Allelic loss: see also Loss of heterozygosity
cromosome 11q13, MEN 1 pituitary adenomas, 1673

Amifostine
cisplatin interactions, cancer, 331
9-Aminocamptothecin
oral capsules
pharmacokinetics and bioavailability,
solid tumors, 1915

9-Amino-20(S)-camptothecin
72-hour infusion, clinical trial, 317
N-4-[2-(2-Amino-3,4-dihydro-4-oxo-7H-
pyrrolo[2,3-d]pyrimidin-5-ylthethyl]-
benzoyl]-l-glutamic acid disodium
salt: see LY231514

Aminoglutethimide
combined with suramin, prostate cancer, 37

6-Aminonicotinamide
cisplatin sensitization, tumor cells, 117

Aminosyn
combined with acivicin
phase I study, advanced solid
malignancies, 2763

Amphiregulin
non-small-cell lung cancer, 241

Androgen deprivation
neoadjuvant
circling prostate cell effects, 2119

Angiogenesis
cervical carcinoma, 2795
MRI assessment, 2305
PD-ECGF, gastric cancer, 429
tumor
and chemotherapy, renal cell
carcinoma models, 1331
and growth factors, non-small-cell
lung cancer, 241
VEGF expression and
lung adenocarcinoma, 1483
non-small cell lung carcinoma, 3017
wtP53 expression and, non-small cell
lung carcinoma, 3017

Angiogenic factors
circulating, breast and gastrointestinal
cancers, 1221

Angiogenin
prognosis and, breast carcinoma, 2161

Animal tumors
natural
photodynamic therapy, 2207

Annexin I
bronchoalveolar lavage fluids, 2559

Anthracrycline
combined with dexverapamil
phase II study, metastatic breast
cancer, 1451

Antiangiogenic factors
circulating, breast and gastrointestinal
cancers, 1221

Antibodies
anti-CD48 IgG2a
antitumor activity, 895
anti-idiotypic
cell-mediated responses, melanoma, 2363

anti-idiotypic GD2 mimic
antibody responses, melanoma, 1117

anti-p53
oral carcinoma, 2147
serum, lung carcinoma, 3025

bispecific
lysis of TAG-72-expressing cells,
2237
vaccine-coupled, T-cell stimulation,
721

BrE-3, radiolabeled humanized
localization, advanced breast cancer,
1679

Anticancer drugs
Twenty-first Richard and Hinda
Rosenthal Foundation Lecture, 1079

Antifolates
antipurine activity potentiation by
dipyridamole, 2895

ex vivo activity, childhood leukemia,
2399

Antigens
loss
immunotherapy, neuroblastoma, 2135
protein
selection for immune attack, 2669
target, prostate cancer immunotherapy,
295

umor
selection for immune attack, 2669

Antisense
thymidylate synthase, 2229

Antitubulin agents
temperature interactions, 1563

APC: see 7-Ethyl-[4-N-(5-
Aminopentanoic acid)-1-
piperidino)carbonyloxycamptothecin

Apheresis products
germ cell tumor cells, PCR, 93

Apoptosis
induction
ATRA, non-small-cell lung cancer
cells, 1345
calphostin C, acute lymphoblastic
leukemia cells, 2967
8-Cl-cAMP and retinoic acid synergy.
CHP-100 cells, 755
estramustine, malignant glioma, 87
flavopiridol, esophageal cancer cells,
2885
HPR, non-small-cell lung cancer
cells, 1345
topotecan sensitivity and, ovarian
tumors, 261
inhibition
K-Ras and, colon carcinoma cells,
2841
photoactivated calphostin C-induced,
2391

Apoptosis-regulating proteins
combination therapy outcome and,
esophageal squamous cell carcinoma,
2991

Apoptosis regulators

Abdominal carcinoma
dendritic cells, 799

β2-4-Acylglycalsaminyl-transf erase
mRNA, metastatic melanoma, 411

Activin
combined with aminosyn
phase I study, advanced solid
malignancies, 2763

Actinomycin
antitumor activity, 171

Adenocarcinoma
esophageal
tumor-associated uPA, 1755

lent
angiogenesis and VEGF expression,
1483

pancreatic
orthotopic model, SCID mice, 879

plasma K-ras mutations, 1527

pancreatic ductal
blood CEA mRNA, quantitative
analysis, 855
dThdPase expression, 1619

prostate
growth inhibition by CEP-751, 1887

homoygous PTEN deletions, 811

prognostic transcription factors, 2153

Adenoma
down-regulated in adenoma DRA gene
expression, colon tumor progression,
1857

pituitary
cromosome 11q13 allelic loss, MEN
1, 1673

Adenovirus
CD80-adenovirus
combined with IL-12, CTL induction,
713
gene delivery
enhancement by FGFR2, 2455
p16INK4A gene therapy, head and neck
squamous cell cancer, 1697
p53 gene therapy
combined with paclitaxel, 835
hepatocellular carcinoma, rat model,
1649
recombinant
intra-arterial delivery, rat model, 1649

African-Americans
prostate cancers
comparative genomic hybridization,
1273

AG17
chemosensitization, glioblastoma cells,
773

AIB1 gene
amplification, breast carcinoma, 2925

Alkaline phosphatase
TIA-1 binding, hepatocellular
carcinoma, 2771

O^-Alkylguanine-DNA-alkyltransferase
heterogeneity, blood and bone marrow
mononuclear cells, 475
expression, cutaneous malignant melanoma, 1865
Arabinosylcytosine
ara-UTP accumulation, acute myelogenous leukemia therapy, 1719
Arabinosyluracil 5'-triphosphate accumulation
ara-C therapy, acute myelogenous leukemia, 1719
Aromatase
inhibition by exemestane, 2089
Aromatase inhibitors
and FGF-transfected MCF-7 cells, 697
Aromatic fatty acids
growth inhibition, ovarian tumor cells, 3069
Asparaginase
myeloid leukemia, 3051
Azido-3'-deoxythymidine
BCI-xA expression esophageal squamous cell carcinoma, 577
ovary, 517
BCI-xB expression, ovary, 517
BCNU: see 1,3 Bis(2-chloroethyl)-1-nitrosourea
Benzo[a]pyrene diol epoxide sensitivity, head and neck squamous cell carcinoma, 1773
Benzylicyloxyridine phase I studies, 1165
β²-Benzylguanidine
intrahepatic, pharmacokinetics, 2891
BESpm: see N³,N⁴'-Bis(ethyl)spermine
Biomarkers
and chemoresponse, gastric cancer, 1469
nonmetastatic vs metastatic invasive bladder cancer, 1267
1,3 Bis(2-chloroethyl)-1-nitrosourea chemosensitization by AG17, glioblastoma cells, 773
Bis-chloroethylnitrosourea: see 1,3 Bis(2-chloroethyl)-1-nitrosourea
N³,N⁴'-Bis(ethyl)spermine
growth inhibition, small cell lung cancer cells, 1557
sensitivity active SSAT copies and, 2003
Bladder
mitomycin C uptake, 139
Bladder carcinoma
bladder wash MMP-9 expression, 3011
diagnosis hTR vs telomerase activity, 1949
invasive nonmetastatic vs metastatic, biomarker study, 1267
p16 copy number changes microsatellite vs QPCR analysis, 441
progression p53- and RB-related, 829
transitional cell complement factor H-like protein, 2511
telomerase activity, 535
urinary hTERT expression, 2807
Bladder washes
MMP-9 expression, bladder carcinoma, 3011
Blood
peripheral: see Peripheral blood portal: see Portal blood
Blood-brain barrier
ara-C permeability cranial irradiation and, pediatric acute leukemia, 69
B lymphocytes
non-Hodgkin's lymphoma relapsed, phase II bolus anti-B4-blocked ricin, 2599
BM-40: see Basement membrane 40
Bone marrow
gastric carcinoma micrometastasis, 2129
microscopic neuroblastoma, detection, 2801
mononuclear cells
AGT heterogeneity, 475
tyrosinase mRNA, malignant melanoma, 419
Bone pain
metastatic Sn-117m DTPA treatment, 61
Bone Scan Index
prostate cancer, 1765
Boron neutron capture therapy
PET-based l-10B-BPA, glioma, 1825, 1833
L-Boronophenylalanine
PET-based boron neutron capture therapy, glioma, 1825, 1833
Brain
cellular lung cancer metastases metabolism and hemodynamics, 2591
Brain tumors
combination dextrozoxane and suprarethal etoposide treatment, 1367
fotemustine activity, human xenografts, 455
permeability, human xenograft in nude rat, 1549
prognosis gene amplification and, 215
BRCAl
mutations, ovarian carcinoma frequency, 2433
Japanese women, 235
BrE-3 antibody
radiolabeled immunolized localization, advanced breast cancer, 1679
Breast cancer
advanced bcl-2 expression and chemotherapy resistance, 2331
combination ATTRA and tamoxifen treatment, 635
In huBrE-3 antibody localization, 1679
posttransplant paclitaxel therapy, 2717
AIBI gene amplification, 2925
BRCAl mutations, ovarian carcinoma, 235, 2433
caveolin expression, 1873
cellular features, 2931
CG117 index, 671
CGB prognostic value, 671
chemotherapy sensitivity induction by heregulin, 1005
circulating angiogenic and antiangiogenic factors, 1221
circulating HGF levels, 659
circulating sE-selectin, 373
combination Ad-mediated p53 gene therapy and paclitaxel, 835
DPD activity, 325
EGF-genistein cytotoxic activity, 901
EGFR, Her-2/neu, and p21coexpression, 913
endocrine therapy, 527
genetic evolution patterns, 913
inhibition AZT, 693, 2569
α-fetoprotein, xenografts, 2877
α6β4 integrin expression, 407
intracranial
cyclin D1 overexpression, 847
invasion
ICAM-1 expression, 31
phagocytosis and, 507
leflunomide metabolite analogue against, 2657
MDR1 expression, 1533
MDR1 Pgp expression and function, 389
metastatic
combination desverapamil plus anthracycline therapy, phase II study, 1451
escalating dose paclitaxel therapy, 1689
tamoxifen response, hsp27 and hsp70 and, 1263
MCP expression, 1533
node-negative
PAI-1 levels, 177
p53 levels, 189
p53 mutations, 1597
tPA levels, 177
uPA levels, 177, 189
peripheral blood cells
detection by RT-PCR for EGFR, 3037
prognosis
angiogenin and, 2161
FGF-2 and, 2939
PSA, 1489
proliferative responses to HER-2 peptides, 2015
reurrence, ipsilateral
CSF-1R expression, 1851
retroviral sequence expression, 2565
RHAMM overexpression, 567
sequential paclitaxel/cyclophosphamide and G-CSF treatment, hematological toxicity, 349
silymarin anticarcinogenic effects, 1055
somatostatin receptor status, 2047
tamoxifen response
HER-2 expression and, 7
MRI, 2299
telomerase expression, 229
telomerase-negative
telomerase activity, 435
vascular integrin αβ, 2625
xenografts
DOTA-peptide-ChL6, 2483
Breast lesions
benign
flow cytometric DNA analysis, 1543
4-(3′-Bromo-4′-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline
cell invasion inhibition, glioblastoma, 2463
cytotoxic activity, glioblastoma, 1405
Bronchial epithelium
hnRNP A2/B1 expression, chronic smokers, 1631
Bronchial preneoplasia
immunohistochemistry, 1609
Bronchoalveolar lavage fluids
annexin I, 2559
Bryostatin 1
antitumor activity, diffuse large cell lymphoma xenografts, 1305
combined with aurisatin PE, chronic lymphocytic leukemia treatment, 1337
combined with 2-chlorodeoxyadenosine, chronic lymphocytic leukemia treatment, 445
phase 1b trial, 611
BSI: see Bone Scan Index
3,5-di-tert-Butyl-4-hydroxybenzylidenemalononitrile: see AG17
Bystander effect
wild-type p53 gene therapy, head and neck squamous cell carcinoma, 2521

C
81C6
mouse/human chimeric, stability, 2495
C225
growth inhibition, renal cell carcinoma xenografts, 2957
Cachexia
TNF and, prostate cancer, 1743
Cadherin-6
prognosis and, renal cell carcinoma, 2419
Calphostin C
apoptosis induction, acute lymphoblastic leukemia cells, 2967
photoactivated apoptosis, 2391
Cancer: see Carcinoma
Cancer chemotherapy: see Chemotherapy
Cephalotaxine
combined with leucovorin
phase I study, intractable solid tumors, 2755
efficacy
enhancement by taxanes, 1013
pharmacokinetics
food effects, 941
Carboplatin
combination ifosfamide, carboplatin, and etoposide with etanidazole and stem cell support, 1443
Carboxyliesterase
rabbit liver
APC conversion to SN-38, 3089
Carcinobromyric antigen
anti-CEA single-chain immunotoxin
growth inhibition, colorectal carcinoma, 2825
expression
drug-induced increase, colon carcinoma, 2473
mRNA
blood, pancreatic ductal adenocarcinoma, 855
polyadenylate immunization against, 2903
serum, colorectal cancer, 1511
Carcinoma: see also specific sites, types advanced
IL-12 responsiveness, differential, 2425
9-cis-retinoic acid, phase I study, 1437
tallimustine effects, phase I trial, 53
irinotecan metabolism, 2747
Cardiac trabeculae
contractile failure after doxorubicin treatment, 1031
Cathespin B
serum, colorectal cancer, 1511
Caucasian Americans
prostate cancers
comparative genomic hybridization, 1273
Caveolin
expression, prostate and breast cancer, 1873
CC49
combined with IFN-γ, prostate cancer, 643
CD5
lymphoma
3′,4′,5′-T101, phase I study, 2691
CD9
eexpression, colon cancer, 1507
CD28
eexpression, multiple myeloma, 1521
CD33
anti-CD33 mAb HuM195, myelogenous leukemia, 1421
CD40
eexpression, osteosarcoma and Ewing’s sarcoma cells, 1843
CD44
eexpression
and prognosis, colorectal cancer, 21
CD48
anti-CD48 IgG2a antibody
antitumor activity, 895
CdA: see Cladrabine
CD80-adenovirus
combined with IL-12
CTL induction, 713
Cell cycle
arrest
G1, CDK4 downregulation by paclitaxel and, 3065
α-myc and, mammary epithelial cells, 1813
Cell differentiation
enhancement
phenylbutyrate, colon carcinoma, 2503
Cell growth: see also Tumor growth
inhibition
anti-CEA single-chain immunotoxin, colorectal carcinoma, 2825
aromatic fatty acids, ovarian tumors, 3071
AZT, breast cancer, 693, 2569
BEspm, small cell lung cancer, 1557
C225 mAb, renal cell carcinoma xenografts, 2957
enhancement by phenylbutyrate, colon carcinoma, 2503
α-fetoprotein, breast cancer xenografts, 2877
vitamin D, colon carcinoma xenografts, 2869
rNEP effects, lung carcinoma, 2849
Cell-mediated immunity
anti-idiotypic antibody responses, melanoma, 2363
Cellular fluorescence
native, head and neck cancer, 1177
Central nervous system tumors
Combination dextroamphetamine and supralethal etoposide treatment, 1367

**CEP-751**
tumor growth inhibition, prostate adenocarcinoma, 1887

**Cervical carcinoma**
angiogenesis, 2795
MRI assessment, 2305
gene profiling
cDNA expression array, 3045
histologically negative lymph nodes
HPV DNA, 979
HPV lipopeptide vaccine response, 2103
squamous
22–1–1 Ag expression, 1517

**Cervical intraepithelial neoplasia**
DFMO dose de-escalation trial, 303
epidermal growth factor receptor expression, 1383

**Chemosensitivity**
glutathione system, ovarian cancer, 1737
and p53 function, 1047
tumor
thyminidine phosphorylase and, 2371

**Chemosensitization**
AG17, glioblastoma cells, 773

**Chemotherapy**
high-dose
resistance, acute in vivo, 483
innovation, 2573
modulation by green tea, 153
non-small cell lung cancer, 1088
5-oxo-L-prolinease, humans and rats, 131
resistance
bcl-2 expression and, advanced breast carcinoma, 2331
response
biomarkers and, gastric cancer, 1469
summation dose intensity, 2027
tumor angiogenesis and, renal cell carcinoma models, 1331

**Children:** see Pediatrics

**Chinese hamster ovary cells**
soluble IL-1R
combined with high-dose IL-2, phase I trial, 1203

8-Chlorocyclic-AMP
retinoic acid synergy
apoptosis induction, CHP-100 cells, 755

2-Chlorodeoxyadenosine
combined with bryostatin 1, chronic lymphocytic leukemia treatment, 445

**Cholesterol sulfate**
coexpressed with cytokeratin, uterine cervical carcinoma, 2985

**CHOP**
FUS-CHOP fusion transcripts, soft tissue liposarcoma, 1779

**Chorionic gonadotropin β**
prognostic value, breast carcinoma, 671

**CHP-100 cells**
apoptosis induction by 8-CI-cAMP and retinoic acid synergy, 755

**Chromosome 10q**
loss
and survival, glioma, 2447

**Chromosome 11q13**
allelic loss, MEN 1 pituitary adenomas, 1673

**Chromosome 11q23**
loss of heterozygosity, head and neck squamous cell carcinoma, 2787

**Chromosome 12p11-13**
translocations
methotrexate polyglutamates and, childhood pro-B ALL, 183

**Chromosome 18q**
deletions, head and neck cancer, 539
loss of heterozygosity, cohesive-type gastric cancer, 973

**Chromosomes**
alterations
prostate cancers, African-Americans and Caucasian Americans, 1273
translocation t(8;21), acute myeloid leukemia, 3051

**Clarinil**
aminolane interactions, cancer, 331
antitumor activity
batimastat and, ovarian carcinoma xenografts, 985
sensitization by 6-aminonicotinamide, tumor cells, 117

**Cladribine**
nucleotides
intracellular pharmacokinetics, chronic lymphocytic leukemia, 653

**Cloning assay**
oxaliplatin cytotoxicity, 1021
c-myc
and cell cycle, mammary epithelial cells, 1813

**Colon carcinoma**
apoptosis inhibition
K-Ras and, 2841
CEA expression
drug-induced increase, 2473
cell differentiation
enhancement by phenylbutyrate, 2503
FLUra cytotoxicity
tomudex pretreatment and, 469
growth inhibition
enhancement by phenylbutyrate, 2503
vitamin D, xenografts, 2869
irinotecan efficacy and pharmacology, xenografts, 743
liposomal GL142711C antitumor activity, xenografts, 3077
MRP1/C9D9 expression, 1507
progression
DRA expression, 1857
recurrent
p53 expression and, 1227
thymidylate synthase expression and, 1227
sequential gemcitabine and FdUrd cytotoxicity, HT-29 cells, 2811
synergism between raltitrexed and irinotecan, 1323

**Colonocytes**
exfoliated DNA, colorectal cancer screening, 337

**Colon-stimulating factor receptor**
expression, ipsilateral breast cancer recurrence, 1851

**Colorectal carcinoma**
advanced
IL-12 and IL-10 production, 1943
PZDH, phase II studies, 929

**BAX mutations, 1071**
chemosensitivity
thymidine phosphorylase and, 2371
circulating cells, 343
comparative genomic hybridization analysis, 879
disseminated
p53 point mutations, 1243
thymidylate synthase mRNA levels, 1243
growth inhibition
anti-CEA single-chain immunotoxin, 2825
hereditary nonpolyposis
p21(WAF1/CIP1) expression, 1251
Mab-treated
metastasis, immunopathology, 1921
metastatic
combination 5-FU plus levamisole treatment, 935
p21(WAF1/CIP1) expression, 1251
prognosis
CD44 expression and, 21
screening
exfoliated colonocyte DNA, 337
serum cathepsin B and CEA, 1511
staging
preoperative serum VEGF, 1279
TP53 gene mutations and, 203
vitamin D receptor expression, 1591

**Comparative genomic hybridization**
colorectal carcinoma analysis, 879
prostate cancers, African-Americans and Caucasian Americans, 1273

**Complementary DNA expression array**
gene profiling, cervical carcinoma, 3045

**Complement factor H**
bladder carcinoma, 2511

**Complement factor H-like protein**
bladder carcinoma, 2511

**Contraction**
failure after doxorubicin treatment, 1031

**CPT-11:** see Irinotecan

**Cranial irradiation**
and BBB permeability to ara-C, pediatric acute leukemia, 69

**Cremophor EL**
combined with bolus doxorubicin, 2321
disposition, 1937

**Cross-linked gelatin matrix**
phagocytosis
breast carcinoma invasion and, 507

**Cutaneous disease**
Npe6 photodynamic therapy, 2741

**Cutaneous malignant melanoma**
apoptosis regulator expression, 1865

**Cutaneous toxicity**
Doxil-induced
pyridoxine and, 1567
α-Cyano-β-hydroxy-β-methyl-V-[4- (trifluoromethoxy)phenyl] propenamide
cytotoxicity activity, breast carcinoma, 2657

**Cyclin D1**
CCND1 gene
human papillomavirus infection and, laryngeal squamous cell carcinoma, 2585
overexpression
breast hyperplasia and intraductal carcinoma, 847
prognosis and, extremity soft-tissue sarcomas, 2377
polymorphisms, head and neck squamous cell carcinoma, 2411
Cyclin-dependent kinase 4
downregulation by paclitaxel, gastric carcinoma, 3063
overexpression, soft-tissue sarcoma, 1065
Cytophosphamide
combined with paclitaxel and G-CSF, hematological toxicity, breast cancer, 499
Cytoxan
Cytokine-block assay
lung cancer, 677
Cytotherat
coexpression with cholesterol sulfate, uterine cervical carcinoma, 2985
Cytokinesis-block assay
tumor levels
DMDC activity and, 493
Cytokeratin
paclitaxel systemic exposure enhancement, 2293
Cytarabine
isolated trisomy 8 in acute myeloid leukemia therapy, 1235
Cytidine deaminase
tumor levels
DMDC activity and, 493
Cytokinesis-block assay
tumor levels
DMDC activity and, 493
Cytokinesis-block assay
tumor levels
DMDC activity and, 493
Cytotoxicity
anti-p185-RTA combined with anti-EGFR-RTA, 2545
EGF-genistein, breast cancer, 901
leflunomide metabolite analogue, breast carcinoma, 2657
oxaliplatin, cloning assay, 1021
paclitaxel
Raf-1 kinase activity and, 1111
sequential gemcitabine and FdUrD cytotoxicity, HT-29 colon carcinoma cells, 2811
topotecan exposure, neuraxis, 2537
WHI-P154, glioblastoma cells, 1405
Cytotoxic T lymphocytes
human
antitumor effects, 1135
induction by CD80-adenovirus and IL-12, 713
abdominal carcinoma, 799
-breased tumor vaccines
peripheral blood stem cell transplantation and, 2709
ld-pulsed vaccination, multiple myeloma, 957
recruitment and activation, renal cell carcinoma, 585
2'-Deoxy-2'-methylenecytidine
activity
Cycl deaminase tumor levels and, 493
N-Demethyl topotecan
clearance
phenytoin effects, medulloblastoma, 783
Dexrazoxane
combined with supralethal etoposide, brain tumors, 1367
Dexverapamil
combined with anthracycline
phase II study, metastatic breast cancer, 1451
Diethylretinamipentacetic acid
Sn-117m metastatic bone pain treatment, 61
α-Difluoromethylornithine
dose de-escalation trial, cervical intraepithelial neoplasia, 303
Dihydrofolate reductase
antifolate inhibitors
ex vivo activity, childhood leukemia cells, 2399
Dihydroxyimidine dehydrogenase
activity, breast cancer, 325
mutations
5-FU toxicity and, 2999
1,25-Dihydroxy-16-ene-23yne-26,27-hexafluoro-19-nor-cholecalciferol
growth inhibitory effects, colon carcinoma xenografts, 2869
1,25-Dihydroxyvitamin D3, growth inhibitory effects, colon carcinoma xenografts, 2869
Dipyridamole
antifolate potentiation, 2895
Disialoganglioside GD2
anti-idiotypic antibody mimic, 1117
immunotherapy, neuroblastoma, 2135
DMBT1 gene
deletions, glioma, 2447
DNA
Epstein-Barr virus serum, nasopharyngeal carcinoma, 665
exfoliated colonocyte, colorectal cancer screening, 337
HPV, histologically negative lymph nodes, 979
DNA analysis
flow cytometric
benign breast lesions, 1543
FNA, invasive carcinomas, 1789
DNA repair mismatch
drug resistance role, 1
medulloblastoma, 1415
DNA topoisomerase I
inhibition
pharmacodynamics, upper gastrointestinal malignancies, 545
pyrazoloacridine effects, 683
DNA topoisomerase II
dexrazoxane rescue
combined with supralethal etoposide, brain tumors, 1367
pyrazoloacridine effects, 683
Dolastatin 10
combined with bryostatin 1, chronic lymphocytic leukemia treatment, 1337
DOTA: see 1,4,7,10-
Tetraazacyclododecane-N,N',N'',N''-
tetraacetic acid
Down-regulated in adenoma (DRA) gene
expression, colon tumor progression, 1857
Doxorubicin
anthracycline disaccharide analogue
MEN 10755
antitumor activity, tumor xenografts, 2833
combined with suramin, prostate cancer treatment, 1193
contractile failure after treatment with, 1031
free
antitumor activity, mouse lymphoma model, 499
liposomal
antitumor activity, mouse lymphoma model, 499
cutaneous toxicity, pyridoxine and, 1567
and monoclonal phagocytic system phagocytic function, 111
pharmacodynamics, prostate tumors, 277
sensitivity
induction by heregulin, MCF-7 cells, 1005
Drug delivery
brain tumors, human xenograft in nude rat, 1549
Drug monitoring
therapeutic
oral etoposide, advanced non-small cell lung cancer, 1705
Drug resistance: see also Multidrug resistance
DNA mismatch repair role, 1
gene expression, prostate cancer, 1393
Drugs: see also specific drugs
antitumor
Twenty-first Richard and Hind Rosenthal Foundation Lecture, 1079
Drug sensitization
and wtp53 overexpression, rhadomyosarcoma, 145
Ductal adenocarcinoma
pancreatic
blood CEA mRNA. quantitative analysis, 855
dThDpase expression, 1619
Dysplasia
TG-α and EGFR modulation, 13
EC 3.4.24.11: see Neutral endopeptidase, recombinant
Ecteinascidin-743
antitumor activity, ovarian carcinoma xenografts, 1977
Elk2/HTK-1: see Lerk-5/Eplg5
Endocrine therapy
breast cancer, 527
Endometrial carcinoma
BAX mutations, 1071
Ki-67 expression and, 2779
PTEN mutations, 3005
synchronous with ovarian carcinoma
PTEN gene, 2577
Endothelial cells
gene therapy vehicles, ovarian carcinoma, 265
env gene
retroviral sequences
expression, breast carcinoma, 2565
Epidermal growth factor
cell cycle progression
c-myc and, mammary epithelial cells, 1813
EGF-genistein conjugate
cytotoxic activity, breast cancer, 901
recombinant human
EGF-Genistein conjugate, 1125
related growth factors
neuangiogenesis and, non-small cell lung cancer, 241
Epidermal growth factor receptor
anti-EGFR mAb C225
growth inhibition, renal cell carcinoma xenografts, 2957
anti-EGFR-RTA immunotoxin therapy, cytotoxicity, 2545
coexpression with Her-2/neu and p21WAF1, breast cancer, 913
expression, cervical intraepithelial neoplasia, 1383
modulation
head and neck squamous cell carcinoma, 13
PKA1 interactions, 821
prognostic factor, glioblastomas, 2383
RT-PCR
peripheral blood cancer cell detection, breast carcinoma, 3037
Epithelial ovarian carcinoma
chemoresistant
glutathione system, 1737
GST genotypes and, 2439
Epithelium
bronchial
hnRNP A2/B1 expression, chronic smokers, 1631
mammary
c-myc and cell cycle, 1813
Eplg5
mRNA overexpression, malignant melanomas, 791
Epstein-Barr virus
DNA
serum, nasopharyngeal carcinoma, 665
Esophageal adenocarcinoma
prognosis
tumor-associated uPA and, 1755
Esophageal carcinoma
apoptosis induction by flavopiridol, 2885
squamous cell
Bcl-XL expression, 577
combination therapy, apoptosis-regulating proteins and, 2991
stromelysin-3, BM-40/SPARC, and MET overexpression, 1375
survival
p21WAF1 and, 2615
vascular endothelial growth factor, 2195
Estramustine
apoptotic tumor cell death, malignant glioma, 87
prostate tumor tissue uptake, 2079
Etanidazole
combined with high-dose ICE and stem cell support, 1443
7-Ethyl-(4-N-(5-Aminopentanoic acid)-1-piperidino)carbonyloxyacamptothecin
conversion to SN-38 by rabbit liver carboxylesterase, 3089
7-Ethyl-10-hydroxycamptothecin
APC conversion by rabbit liver carboxylesterase, 3089
disposition, neuroblastoma, 455
Etoposide
combination ifosfamide, carboplatin, and etoposide with etanidazole and stem cell support, 1443
combined with paclitaxel
sequence-dependent schedule, advanced non-small cell lung cancer, 2723
combined with topotecan, sequentially, 1459
oral
therapeutic drug monitoring, advanced non-small cell lung cancer, 1705
sensitivity
induction by heregulin, MCF-7 cells, 1005
supraepithelial
combined with dextrazoxane, brain tumors, 1367
Ewing’s sarcoma
apoptosis induction by 8-Cl-cAMP and retinoic acid synergy, CHP-100 cells, 755
CD40 expression, 1843
Exemestane
aromatase inhibition, 2089
Exfoliated colonocytes
DNA, colorectal cancer screening, 337
Exotoxins
recombinant heregulin-Pseudomonas, 993
Extremity soft-tissue sarcomas
prognosis
cyclin D1, 2377
Fab fragments
mAb C224
SEA fusion protein PNU-214565, phase 1 repeat dose, 1903
Fas ligand
secretion by prostate cancer cells, 1803
Fatty acids
aromatic
growth inhibition, ovarian tumor cells, 3071
FCE 24517: see Tallimustine
α-Fetoprotein
growth inhibition, breast cancer xenografts, 2877
Fibroblast growth factor
ICI 182,780 effects, transfected MCF-7 cells, 697
Fibroblast growth factor 2
adenoviral gene delivery enhancement, 2455
Fibroblast growth factor 2 receptors
prognostic value, breast carcinoma, 2939
Fibroblasts
telomerase activity
and p53 status, 1573
Fine-needle aspirates
flow cytometric DNA analysis, invasive carcinomas, 1789
thyroid samples
telomerase activity, 1965
Flavopiridol
apoptosis induction, esophageal cancer cells, 2985
Flow cytometry
DNA analysis
benign breast lesions, 1543
FNA, invasive carcinomas, 1789
Fludarabine
combined with ara-C infusions
pharmacology, pediatric relapsed leukemia, 45
Fluorescence
native cellular, head and neck cancer, 1177
[F-18]Fluorodeoxyglucose positron emission tomography
quantitative, sarcoma, 1215
5-Fluoro-2′-deoxyuridine
combined with gemcitabine, sequential cytotoxicity, HT-29 colon carcinoma cells, 2811
5-Fluorouracil
association with oxaliplatin, 2529
combined with cis-platinum
biomarkers and, gastric cancer, 1469
combined with γ-IFN or folinic acid
CEA expression increase, colon carcinoma, 2473
combined with levamisole
homocysteine levels, 2125
combined with gemcitabine
metastatic colorectal cancer treatment, 935
cytotoxicity
tomudex pretreatment and, colon carcinoma, 469
i.v.
comparison with combination uracil and florasfurfur, 2085
monitoring
clinical response, locally advanced head and neck carcinoma, 2039
toxicity
dihydropyrimidine dehydrogenase
gene mutations and, 2999
Folinic acid
combined with 5-fluorouracil
CEA expression increase, colon carcinoma, 2473
Food
and cephalamine pharmacokinetics, 941
Fotemustine
activity, medulloblastoma and malignant
glioma xenografts, 463
Ftorafur: see N\tau-(2′-Tetrahydrofuryl)-5-
fluourouracil
FUS-CHOP fusion transcripts
soft tissue liposarcoma, 1779
Fusion proteins
heregulin-Pseudomonas exotoxin,
recombinant, 993
Fusion transcripts
FUS-CHOP, soft tissue liposarcoma,
1779

G

G250
\textsuperscript{\textit{T}}\textsuperscript{1}-labeled
radioimmunotherapy, metastatic renal
cell carcinoma, 2729
\gamma\textsuperscript{\textit{r}}-radiation
mutagen sensitivity
survival and, glioma, 3031
Ganciclovir
resistance
and HSV-TK, gastrointestinal tumor
cells, 731
Gastric carcinoma
angiogenesis
PD-ECGF, 429
BAX mutations, 1071
decreased downregulation by paclitaxel,
3063
chemoresistance
biomarkers and, 1469
cohesive-type
chromosome 18q loss of
heterozygosity, 973
combination 5-fluorouracil and cis-
platinum treatment
biomarkers and, 1469
microsatellite instability, 1749
MT1-MMP-MMP-2, 2179
MUC1 and MUC2 mucins, 2605
Gastrointestinal carcinoma
advanced
PNL-24565 therapy, phase I repeat
dose, 1903
circulating angiogenic and
antiangiogenic factors, 1221
circulating leptin levels, 2977
\textit{HSV-TK}-transduced
ganciclovir resistance, 731
Gelonin
recombinant
HuM195-rGel conjugate, antileukemic
activity, 1971
Genetinibine
combined with FdUrd, sequential
cytotoxicity, HT-29 colon carcinoma
cells, 2811
Gene amplification
and prognosis, brain tumors, 215
Genes
differentially expressed
cDNA expression array profiling,
cervical carcinoma, 3045
drug resistance
expression, prostate cancer, 1393
Gene therapy
adenoviral
enhancement by FGF2, 2455
adenovirus-mediated p\textit{16}\textsuperscript{NKA/AA}, head and
neck squamous cell cancer, 1697
adenovirus-mediated p\textit{53}
combined with paclitaxel, 835
hepatocellular carcinoma, rat model,
1649
combination E\textit{2}F and p\textit{53}, head and
neck squamous cell carcinoma, 2265
dothelinic cell, ovarian
carcinoma, 265
wild-type p\textit{53}
bystander effect, head and neck
squamous cell carcinoma, 2521
Genetic evolution
patterns, breast cancer, 913
Genistein
B43-genistein immunoconjugate
toxicity and pharmacokinetics,
nonhuman primates, 165
EGF-genistein conjugate, 1125
cytotoxic activity, breast cancer, 901
Genotypes
glutathione S-transferase, epithelial
ovarian carcinoma, 2439
Germ cell tumor cells
apoptosis, products, PCR, 93
GI147211
phase I trial, 595
GI147211C
liposomal
pharmacokinetics and antitumor activity,
HT29 colon tumor xenografts, 3077
Glial tumors
prognostic factors
epidermal growth factor receptor and
labeling index, 2383
Glioblastoma
AG17 chemosensitization, 773
invasion
inhibition by WHI-P131 and WHI-
P154, 2463
WHI-P154 cytotoxic activity, 1405
Glioma
DMBTI deletions, 2447
malignant
estramustine-induced apoptotic tumor
cell death, 87
fomustine activity, xenografts, 463
MMAC/Pten deletions, 2447
PET-based boron neutron capture
therapy with \textit{L-\textit{2}}\textsuperscript{\textit{B}}-BPA, glioma,
1825, 1833
PKCa expression, 1797
survival
chromosome 10q loss and, 2447
\gamma\textsuperscript{\textit{r}}-ray mutagen sensitivity and, 3031
Glucose
lung tumor metabolism, dynamic T1-
weighted MRI, 949
\gamma\textsuperscript{\textit{G}}-Glutamyl cysteine synthetase
glutathione upregulation, chemoresistant
ovarian cancer, 1737
MRP upregulation, chemoresistant
ovarian cancer, 1737
Glutathione
chemoresistant ovarian cancer, 1737
Glutathione S-transferase
genotypes, epithelial ovarian carcinoma,
2439
Graft-versus-leukemia effect
antagonistic systemic IL-2 effects,
murine model, 2635
cluster formation, 3095
Granulocyte colony-stimulating factor
combined with
paclitaxel/cyclophosphamide
hematological toxicity, breast cancer, 349
Green tea
chemotherapy modulation, 153
Growth factors: see \textit{also} specific factors
tumor angiogenesis and, non-small-cell
lung cancer, 241

H

Head and neck carcinoma
chromosome 18q deletions, 539
combination Ad-mediated p\textit{53} gene
therapy and paclitaxel, 835
locally advanced
5FU monitoring response, 2039
native cellular fluorescence, 1177
squamoid cell
Bax expression, 2913
Bcl-2 expression, 2913
benzo(a)pyrene sensitivity, 1773
chromosome 11q23 loss of
heterozygosity, 2787
combination E\textit{2}F and p\textit{53} gene
transfer, 2265
cyclin D1 polymorphisms, 2411
p\textit{16}\textsuperscript{NKA/AA} adenovirus-mediated gene
therapy, 1697
TGF-\alpha and EGFR modulation, 13
wild-type p\textit{53} gene therapy, bystander
effect, 2523
Heat shock protein
hs27
and tamoxifen response, metastatic
breast cancer, 1263
hs70
and tamoxifen response, metastatic
breast cancer, 1263
Hematopoietic stem cell support
autologous
combined with high-dose ICE and
testodazole, 1443
Hepatic perfusion
isolated
capillary leak, 2357
Hepatitis B virus-X protein
human IL-6 gene activation, hepatoma
cells, 1711
Hepatocellular carcinoma
alkaline phosphatase and TJA-I binding,
2771
malignancy, 1475
p53 gene therapy, rat model, 1649
Hepatocyte growth factor
circulating levels, breast cancer, 659
Hepatoma
human IL-6 gene activation by HBV-X,
1711
Heregulin
\textit{Pseudomonas} exotoxin fusion proteins,
recombinant, 993
Heregulin \beta-2
chemotherapy sensitivity induction, MCF-7 cells, 1005
**Her-2/neu**
expression and tamoxifen response, breast cancer, 7
**HER-2/neu-associated peptides**
proliferative responses, breast cancer, 2015
**Herpes simplex virus thymidine kinase**
adenoviral gene delivery enhancement by FGF2, 2455
**HSV-TK** gene
ganclovir resistance and, gastrointestinal tumor cells, 731
**Homocysteine**
levels combination 5-FU plus leucovorin treatment, 2125
**Hormonal therapy**
neoadjuvant circulating prostate cell effects, 2119
**HT29 cells**
liposomal GL14721IC antitumor activity, xenografts, 3077
sequential gemcitabine and FdUrD cytotoxicity, 2811
**HuD**
vaccination growth inhibition, neuroblastoma, 2819
**Human papillomavirus**
DNA, histologically negative lymph nodes, 979
infection **CCND1** gene and, laryngeal squamous cell carcinoma, 2585
**Human papillomavirus type 16**
E7
lipopeptide vaccine, cellular immune responses, 2103
**Hyaluronan-mediated motility, receptor**
overexpression, breast cancer, 567
4-(4'-Hydroxyphenyl)-amino-6,7-dimethoxyquinazoline
cell invasion inhibition, glioblastoma, 2463
**N-(4-Hydroxyphenyl)retinamide**
apoptosis induction, non-small-cell lung cancer cells, 1345
**Hyperparathyroidism**
uremia, 211
**Hyperplasia**
**breast**
cyclin D1 overexpression, 847
**Hyperplasia**
antitubulin agents and, 1563
local mAb catabolism and, 2071

**I**

**Ibuprofen**
combined with radiotherapy antitumor effects, prostate carcinoma cells, 763
**ICE**: see Ifosfamide, carboplatin, and etoposide
IC1 182,780 and FGF-transfected MCF-7 cells, 697
**ICRF-187**: see Dextraoxane
**Idiotype**
anti-idiotype antibodies cell-mediated responses, melanoma, 2363
anti-idiotype antibody GD2 mimic antibody responses, melanoma, 1117
**Idiotypic protein**
pulsed dendritic cells vaccination, multiple myeloma, 957
**Ifosfamide, carboplatin, and etoposide**
combined with etanidazole and stem cell support, 1443
**Immunization**
polynucleotide against carcinoembryonic antigen, 2903
**Immunonogenetics**
anti-B4-blocked ricin phase II bolus, relapsed B-cell non-Hodgkin’s lymphoma, 2599
**Immunodeficiency**
severe combined orthotopic pancreatic adenocarcinoma model, mice, 879
**Immunoglobulin G2**
mouse/human chimeric anti-tenascin mAb 81C6, stability, 2495
**Immunoglobulin G2a**
antitumor activity, 895
**Immunosuppression**
anti-immunotoxin response, mice, 1297
**Immunotherapy**
active combination UVB-irradiated autologous melanoma cells plus DETOX, metastatic melanoma, 619 antigen loss, neuroblastoma, 2135 target antigens, prostate cancer, 295
**Immunotoxins**
anti-CEA single-chain growth inhibition, colorectal carcinoma, 2825
anti-immunotoxin response immunosuppression, mice, 1297 ricin A chain anti-p185-RTA combined with anti-EGFR-RTA, cytotoxicity, 2545 TP3-pokeweed antiviral protein antitumor activity, osteosarcoma xenograft models, 1641
**IND 039655**: see Benzylocyclouridine
**Infection**
human papillomavirus **CCND1** gene and, laryngeal squamous cell carcinoma, 2585
**Inflammatory response**
circulating leptin levels and, gastrointestinal carcinoma, 2977
**Insulin-like growth factor I receptor**
mutant tumor growth inhibition, 2647
**Integrins**
o68 expression, breast carcinoma, 407 a,b vascular, breast carcinoma, 2625
**Intercellular adhesion molecule-1**
expression invasive breast cancer, 31
**Interferon α**
signaling, malignant melanoma, 2219
**Interferon γ**
combined with 5-fluorouracil CEA expression increase, colon carcinoma, 2473 combined with MAb CC49, prostate cancer, 643
**Interleukin 1 receptors**
soluble (CHO) combined with high-dose IL-2, phase I trial, 1203
**Interleukin 2**
combined with radiation, metastatic renal cell carcinoma, 283
dose-response differences, 1287 high-dose combined with s(CHO) IL-1R, phase I trial, 1203 liposomes, anticancer vaccination, 1881 metastases inhibition, prostate carcinoma, 2551 systemic antagonistic effects, murine leukemia model, 2635 systemic therapy, prostate tumors, 2009
**Interleukin 6**
combined with Taxol or vinblastine, myeloma cells, 1039 expression, thyroid carcinoma, 381 human gene activation by HBV-X, hepatoma cells, 1711
**Interleukin 10**
antimetastatic and antitumor activities, prostate tumor cells, 2257 production, advanced colorectal cancer, 1943
**Interleukin 12**
combined with CD80-adenovirus CTL induction, 713 differential responsiveness, advanced cancer patients, 2425 production, advanced colorectal cancer, 1943 recombinant metastatic melanoma, pilot study, 75 subcutaneous, advanced renal cell carcinoma, 1183
**Interleukin 15**
dose-response differences, 1287
**Intraductal carcinoma**
breast cycin D1 overexpression, 847
**Intraepithelial neoplasia**
cervical DFMO dose de-escalation trial, 303 epidermal growth factor receptor expression, 1383
**Invasion**
flow cytometric DNA analysis with FNAs, 1789 ICAM-1 expression, breast carcinoma, 31 inhibition by WHI-P131 and WHI-P154, glioblastoma, 2463 muscle p53, melatothionein, Pgp, and MIB-1 prognostic role, urothelial transitional cell carcinoma, 559
nonmetastatic vs metastatic biomarker study, bladder cancer, 1267 phagocytosis and, breast carcinoma, 507
iodine-131 labeled G250 radioimmunotherapy, metastatic renal cell carcinoma, 2729
5-Iodo-2'-deoxyuridine radiosensitization IPDr prodrug, mouse and human tissues, 99
5-Iodo-2-pyrimidinone-2'-deoxyribose iodine-131
5-Iodo-2'-deoxyuridine radiolabeled radiosensitization prodrug, mouse and human tissues, 99
4-Ipomeanol five-day dose schedule, non-small cell lung cancer, 2095
Irinotecan disposition, neuroblastoma, 455 efficacy and pharmacology, colon xenografts, 743 metabolism, human cancer patients, 2747 mucositis prevention by oral JBT 3002, 2053 synergy with raltitrexed, colon cancer cells, 1323
Isolated hepatic perfusion capillary leak, 2357

J
Japanese women ovarian cancer BRCA1 mutations, 235
JBT 3002 oral mucositis prevention, 2053

K
Ki-67 expression endometrial carcinoma and, 2779
Kinases Raf-1 paclitaxel cytotoxicity and, 1111 K-ras apoptosis inhibition and, colon carcinoma cells, 2841 mutations plasma, pancreatic adenocarcinoma, 1527 plasma, pancreatic cancer, 271 KT6587: see CEP-751 KW-2189 phase I study, 2111

L
Labeling index prognostic factor, glioblastomas, 2383
Laryngeal squamous cell carcinoma CCND1 gene and human papillomavirus infection, 2585

Lectures Twenty-first Richard and Linda Rosenthal Foundation Lecture, anticancer drugs, 1079

Leflunomide metabolite analogue against breast carcinoma, 2657
Leptin circulating levels, gastrointestinal carcinoma, 2977
Lerk-5/Epfg5 mRNA overexpression, malignant melanomas, 791 Lesions: see specific sites, types Letters to the editor re: C. Caserini et al., 3: 955–961, 261 re: S. M. Melana et al., 4: 693–696, 2569
Leucovorin combined with capecitabine phase I study, intractable solid tumors, 2755 combined with 5-FU homocysteine levels, 2125 minimal-dose combined with high-dose trimetrexate, 2981
Leukemia acute pediatric, cranial irradiation and BBB permeability to ara-C, 69 antagonistic systemic IL-2 effects, murine model, 2635 graft-versus-leukemia effect antagonistic systemic IL-2 effects, murine model, 2635 cluster formation, 3095 HuM195-RF1 antileukemic activity, 1971 myelogenous anti-CD33 mAb HuM195, 1421 natural killer cell antileukemia activity, 2859 pediatric antifolate ex vivo activity, 2399 pediatric relapsed combination fludarabine and ara-C infusions pharmacology, 45
Leukemia, acute lymphoblastic apoptosis induction by calphostin C, 2967 B-progenitor cell, childhood MTXPGs and and chromosome 12p11-13 translocations, 183 childhood RFC expression, 2169 Ph-positive tyrosine kinase inhibitors, 1661 toptocan treatment, phase II window study, 2677
Leukemia, acute myelogenous ara-C therapy ara-UTP accumulation, 1719 prognosis retinoblastoma protein expression and, 1955
Leukemia, acute myeloid isolated trisomy 8 cytarabine-based chemotherapy, 1235 MRP1 and MRP2 activity and expression, 1727 translocation t(8;21), 3051
Leukemia, chronic lymphocytic combination auristatin PE and bryostatin 1 treatment, 1337 intracellular CDA nucleotide pharmacokinetics, 653 sequential bryostatin 1 and 2-chlorodeoxyadenosine treatment, 445
Leukemia, chronic myelogenous peripheral blood Ph+ myeloid cells, 861
Levamisole combined with 5-FU, metastatic colorectal cancer treatment, 935 Lipopeptides HPV vaccine, cellular immune responses, 2103 Liposarcoma soft tissue FUS-CHO fusion transcripts, 1779 Liposomes doxorubicin antitumor activity, mouse lymphoma model, 499 cutaneous toxicity, pyridoxine and, 1567 and monoclonal phagocyte system phagocytic function, 111 IL-2, antitumor vaccination, 1881 Liver rabbit carboxylesterase, APC conversion to SN-38, 3089 Lomotrelxol cellular and red blood cell pharmacokinetics, 2349 Loss of heterozygosity chromosome 11q23, head and neck squamous cell carcinoma, 2787 chromosome 18q, cohesive-type gastric cancer, 973 multifocal renal cell carcinoma, 2491 uremia, 211 Lung MRP expression, 2279 NAD(P)H:quinone oxidoreductase, detection, 2065 Lung adenoscarcinoma angiogenesis and VEGF expression, 1483 Lung carcinoma anti-p53 autoantibody monitoring, 1359 cell growth rNEP effects, 2849 cytokinesis-block assay, 677 dynamic T1-weighted MRI, 949 MRP expression, 2279 NAD(P)H:quinone oxidoreductase, detection, 2065 non-small cell advanced, sequence-dependent paclitaxel/etoposide schedule, 2723 advanced, therapeutic drug monitoring of oral etoposide, 1705 angiogenesis, 3017 angiogenesis and growth factors, 241 apoptosis induction by 4HPR vs ATRA, 1345 chemotherapy, 1088 4-ipomeanol five-day dose schedule, 2095 paclitaxel and radiation therapy, phase II trial, 1931 prognosis, microvessel count and, 241
survival, p21<sup>wt16Cip1</sup> and TGF-β1 expression and, 1499
TSP2 expression, 1785
vascular endothelial growth factor expression, 3017
wild-type p53 expression, 3017
oncogene hot spots
PCR-based detection, 641
perfusion and metabolism, dynamic TI-weighted MRI, 949
precursor bronchial lesions
immunohistochemistry, 1609
serum anti-p53 antibodies, 3025
small cell
BESpm growth inhibitory effects, 1557
metastases to brain, metabolism and hemodynamics, 2591
LY231514
phase I study, 605
LY309887
radioimmunoassay, 157
Lymph nodes
histologically negative
HPV DNA, 979
Lymphoblast
CD5<sup>-</sup>CD<sup>90</sup>-T1101, phase I study, 2691
diffuse large cell
bryostatin 1 antitumor activity, 1305
doxorubicin antitumor activity
free vs liposomal, mouse model, 499
non-Hodgkin’s, B-cell
relapsed, phase II bolus anti-B4-blocked ricin, 2599
peripheral blood progenitor cell
mobilization factors, 311

M

M195
humanized
HuM195-rGel conjugate, antileukemic activity, 1971
myelogenous leukemia, 1421
Magnetic resonance imaging
angiogenic activity, cervical carcinoma, 2305
dynamic TI-weighted, lung cancer, 949
tamoxifen breast cancer response, 2299
Malignancy
advanced solid
combination activin and aminosyn, phase I study, 2763
ascites
intraperitoneal BB94, 1899
gastrointestinal
PNU-24565 therapy, phase I repeat dose, 1903
glioma
estramustine-induced apoptotic tumor cell death, 87
estramustine activity, xenografts, 463
hepatocellular carcinoma, 1475
melanoma
bone marrow tyrosinase mRNA marker, 419
IFN-α signaling, 2219
Lerk-5/Eplg5 mRNA overexpression, 791
peripheral blood tyrosinase mRNA marker, 419
melanoma, cutaneous
apoptosis regulator expression, 1865
ovarian lesions
telomerase activity, 399
refractory
bryostatin 1, phase Ib trial, 611
upper gastrointestinal
topoisoerase I inhibition
pharmacodynamics, 545
Mammary carcinoma: see Breast carcinoma
Mammary epithelial cells
c-Myc and cell cycle, 1813
Mammography
-guided fine-needle aspirates
flow cytometric DNA analysis, invasive carcinomas, 1789
Marimastat
and serum tumor markers, 1101
Matrix metalloproteinase
membrane type 1
MMP-2 ratio, gastric carcinoma, 2179
Matrix metalloproteinase-2
MT1-MMP/MMP-2 ratio, gastric carcinoma, 2179
Matrix metalloproteinase-9
expression
bladder washes, bladder carcinoma, 3011
MCF-7 cells
chemotherapy sensitivity induction by heregulin, 1005
FGF-transfected
ICI 182,780 effects, 697
MDA-MB 468 cells
silymarin anticarcinogenic effects, 1055
MDM2: see Mouse double minute-2
cadullohlastoma
fotemustine activity, xenografts, 463
intermittent topotecan exposure efficacy, xenografts, 1995
mismatch repair, 1415
topotecan clearance
phentoyin effects, 783
Melanoma
autologous cells, UVB-irradiated combined with DETOX, metastatic melanoma, 619
cell-mediated responses to anti-idiotypic antibodies, 2363
GD2 mimic antibody responses, 1117
malignant
bone marrow tyrosinase mRNA marker, 419
IFN-α signaling, 2219
Lerk-5/Eplg5 mRNA overexpression, 791
peripheral blood tyrosinase mRNA marker, 419
malignant, cutaneous
apoptosis regulator expression, 1865
metastatic
β2→4GalNac-T mRNA marker, 411
rhHuL-12, pilot study, 75
UVB-irradiated autologous cells plus DETOX immunotherapy, 619
MEN 10755
antitumor activity, tumor xenografts, 2833
Mesna
oral vs i.v. bioavailability, 2313
MEST
overexpression, esophageal carcinoma, 1375
Metalloproteinase inhibitors
BB94
intraperitoneal, malignant ascites, 1899
Metallothionein
prognostic role, muscle-invasive urothelial transitional cell carcinoma, 559
Metastasis
bone pain
Sn-117m DTPA treatment, 61
breast carcinoma
combination dexerapamplus plus antracycline therapy, phase II study, 1451
escalating dose paclitaxel therapy, 1689
tamoxifen response, hsp27 and hsp70 and, 1263
colorectal carcinoma
combination 5-FU plus levamisol treatment, 935
colorectal carcinoma, Mab-treated immunopathology, 1921
inhibition
IL-10, prostate tumor cells, 2257
invasive bladder cancer, biomarker study, 1267
melanoma
β2→4GalNac-T mRNA marker, 411
rhHuL-12, pilot study, 75
UVB-irradiated autologous cells plus DETOX immunotherapy, 619
micrometastasis
gastric cancer to bone marrow, 2129
prostate cancer
inhibition by targeted IL-2, 2551
prostate cancer to bone
Bone Scan Index, 1765
renal cell carcinoma
<sup>1</sup>121-I-G250 radioimmunotherapy, 2729
sequential radiation and IL-2 treatment, 283
carcinoma
small cell lung cancer to brain
metabolism and hemodynamics, 2591
Methotrexate polyglutamates
and chromosome 12p11-13
translocations, childhood pro-B ALL, 183
7-[4-Methylpiperazinomethylene]-10,11-ethylenedioxy-20(S)-camptothecin dihydroloridamide: see GI147211
MIB-1
prognostic role, muscle-invasive urothelial transitional cell carcinoma, 559
Microemtastasis
gastric cancer to bone marrow, 2129
Microsatellites
analysis
p16 copy number change detection, bladder tumors, 441
instability
BAX mutations, 1071
gastric cancer, 1749
Microvessel count
and prognosis, non-small-cell lung cancer, 241

Mimetycin C
bladder tissue uptake, 139

MMAC1/PTEN gene
deletions
Glioma, 2447
homzygous, prostate adenocarcinoma, 811
mutations, endometrial carcinoma, 3005
synchronous endometrial and ovarian carcinoma, 2577

Mono-L-aspartyl chlorin e1
photodynamic therapy, cutaneous disease, 2741

Monooclonal antibody
anti-CD33 mAb HuM195
HuM195-G-Cell conjugate, antileukemic activity, 1971
myelogenous leukemia, 1421
anti-EGFR C225
growth inhibition, renal cell carcinoma xenographs, 2957
anti-tenascin mAb 81C6
mouse/human chimeric, stability, 2495

catabolism
local hyperthermia and, 2071
CC49
combined with IFN-γ, prostate cancer, 643
colorectal carcinoma treatment metastasis, immunopathology, 1921

Mononuclear cells
bone marrow
AGT heterogeneity, 475
peripheral blood
AGT heterogeneity, 475

Mononuclear phagocyte system
phagocytic function
liposomal doxorubicin and, 111

Motility related protein 1
expression, colon cancer, 1507

Mouse double minute-2
-overexpression tumors
therapy, 251

MTS1
mutations, soft-tissue sarcoma, 1065

Mucins
MUC1
expression, gastric carcinoma, 2605
MUC2
expression, gastric carcinoma, 2605

Mucositis
prevention by oral JBT 3002, 2053

Multidrug resistance
MDR1
downregulation by bryostatin 1, diffuse large cell lymphoma xenographs, 1305
expression, breast carcinoma, 1533
MDR1 Pgp
expression and function, breast cancer, 389

Multidrug resistance protein
MRP1
activity and expression, acute myeloid leukemia, 1727

MRP2
activity and expression, acute myeloid leukemia, 1727

MRP gene
expression, breast carcinoma, 1533
expression, lung and lung carcinoma, 2279
upregulation by γ-GCS, chemoresistant ovarian cancer, 1737

Multidrug sensitivity
wild-type p53, 1315

Multiple endocrine neoplasia
type 1
chromosome 11q13 allelic loss, pituitary adenomas, 1673

Multiple myeloma
CD28 expression, 1521
Id-pulsed dendritic cell vaccination, 957

Mutagen sensitivity
γ-ray survival and, glioma, 3031

Mutations
BAX, M1 + cancers, 1071
BRCA1
ovarian carcinoma, frequency, 2433
ovarian carcinoma, Japanese women, 235
dihydropyrimidine dehydrogenase gene 5-FU toxicity and, 2999
hot spot
p53, PCR-based detection, lung cancer, 361
ras, PCR-based detection, lung cancer, 361
insulin-like growth factor I receptor tumor growth inhibition, 2647
K-ras
plasma, pancreatic adenocarcinoma, 1527
plasma, pancreatic cancer, 271
p16/MTS1, soft-tissue sarcoma, 1065
p53
node-negative breast cancer, 1597
point
p53, disseminated colorectal cancer, 1243
PTEN
endometrial carcinoma, 3005
TP53

Myeloid cells
Pho+
peripheral blood, chronic myelogenous leukemia, 861

Myeloma
combination IL-6 with Taxol or vinblastine therapy, 1039
multiple
CD28 expression, 1521
Id-pulsed dendritic cell vaccination, 957

NAD(P)H:quinone oxidoreductase
antitumor quinones
screening system, 3083
lung and lung tumors, detection, 2065

Nasopharyngeal carcinoma
serum EBV DNA, 665
Native cellular fluorescence
head and neck cancer, 1177

Natural animal tumors
photodynamic therapy, 2207

Natural killer cells
activated, human antitumor effects, 1135
antileukemia activity, 2859

Neoangiogenesis
and growth factors, non-small-cell lung cancer, 241

Neoplasia
cervical intraepithelial
DFMO dose de-escalation trial, 303
epidermal growth factor receptor expression, 1383
cervical squamous
22–1–1 Ag expression, 1517
multiple endocrine, type 1
chromosome 11q13 allelic loss, pituitary adenomas, 1673

Neu
see Her-2/neu

Neuraxis
cytotoxic topotecan exposure, 2537

Neuroblastoma
growth inhibition by HuD vaccination, 2819
irinotecan and SN-38 disposition, mice, 455
microscopic
marrow, detection, 2801

Neutral endopeptidase
recombinant
growth effects, lung cancer cells, 2849

NK-92 cells
antileukemia activity, 2859

Non-Hodgkin's lymphoma
B-cell
relapsed, phase II bolus anti-B4-blocked ricin, 2599

Npse: see Mono-L-aspartyl chlorin e1
NSC 366140: see Pyrazolocaridine
NSC 61066: see Perillyl alcohol

NTRK1
rearrangements, papillary thyroid tumors, 223

O

1,25-(OH)2-16-ene-23-yne vitamin D3
toxicity and dose-response studies, transgenic mice, 2253

Oncogenes
hot spots
PCR-based detection, lung cancer, 361

Oral carcinoma
p53 antibodies, 2147
PD-ECGF expression, 1583

Oropharyngeal carcinoma
PD-ECGF expression, 1583

Osteosarcoma
CD40 expression, 1843
TP3-PAP antitumor activity, xenograft models, 1641

YB-1 nuclear expression, 2273

Ovarian carcinoma
adenoviral gene therapy
enhancement by PGF2, 2455
anti-p185-RTA RTA with anti-EGFR-RTA immunotoxin therapy, cytotoxicity, 2545

BRCA1 mutations
3134 Subject Index

frequency, 2433
Japanese women, 235
chemoresistant
glutathione system, 1737
cisplatin antitumor activity
batimatast and, xenografts, 985
combination Ad-mediated p53 gene
therapy and paclitaxel, 835
epithelial
GST genotypes and, 2439
ET-743 antitumor activity, xenografts, 1977
gene therapy
endothelial cell vehicles, 265
growth inhibition by aromatic fatty
acids, 3069
progesterone receptor, 2245
synchronous with endometrial
carcinoma
PTEN gene, 2577
telomerase activity, 399
toptoepecan sensitivity
apoptosis induction and, 261
Ovary
bcl-2 protein family expression, 517
Oxaliplatin
association with 5-FU, 2529
cytotoxicity, cloning assay, 1021
5-Oxo-4-prolinase
characterization, humans and rats, 131

P

p16

copy number changes
microsatellite vs QPCR analysis,
bladder tumors, 441
mutations, soft-tissue sarcoma, 1065
p16

adenoviral gene therapy, head and neck
squamous cell cancer, 1697
p21

expression, pancreatic carcinoma, 1147
p21

coexpression with EGFR and Her-2/neu,
early operable non-small
cell lung cancer, 1913
p21

expressed, colorectal carcinoma, 1251
survival and
esophageal carcinoma, 2615
non-small cell lung cancer, 1499
p53

antibodies
oral carcinoma, 2147
serum, lung carcinoma, 3025
autoantibodies
monitoring, lung cancer, 1359
bladder cancer progression, 829
combined with E2F, gene transfer, 2265
expression
and recurrence, colon cancer, 1227
function
chemosensitivity and, 1047
gene therapy
hepatocellular carcinoma, rat model, 1649
gene therapy, adenoviral
combined with paclitaxel, 835
levels, node-negative breast cancers, 189
mutations
bronchial preneoplasia, 1609
and colorectal cancer, 203
hot spots, PCR-based detection, lung
cancer, 361
node-negative breast cancer, 1597
point, disseminated colorectal cancer, 1243
prognostic role, muscle-invasive
urothelial transitional cell carcinoma, 559
restoration, soft tissue sarcomas, 1985
status
telomerase activity and, sarcoma cells
fibroblasts, 1573
transcription
bronchial preneoplasia, 1609
wild-type
extpression, early operable non-small
cell lung cancer, 3017
genotype, bystander effect, 2521
multidrug sensitivity, 1315
overexpression, drug sensitization
and, 145
p80

anti-p80 TP3-PAP immunotoxin
antitumor activity, osteosarcoma
xenograft models, 1641
p170

anti-p170G0P8, ricin A chain
combined with anti-p185-RTA, cytoxocitiy,
2545
p185

anti-p185-ricin A chain immunotoxin
therapy
cytoxocitiy, 2545
Paclitaxel
activity
solid tumor pathology and, 2949
CDK4 downregulation, gastric
carcinoma, 3063
combined with Ad-mediated p53 gene
therapy, 835
combined with cyclophosphamide and
G-CSF
hematological toxicity, breast cancer, 349
combined with etoposide
sequence-dependent schedule,
advanced non-small cell lung cancer,
2723
combined with radiation therapy
phase II trial, non-small cell lung
cancer, 1931
cytotoxicity
Raf-1 kinase activity and, 1111
escalating dose, metastatic breast cancer
therapy, 1689
posttransplant, advanced breast
carcinoma, 2717
systemic exposure
enhancement by cyclosporin A, 2293

Pain
metastatic bone
Sn-117m DTPA treatment, 61
Pancreatic adenocarcinoma
ductal
blood CEA mRNA, quantitative
analysis, 855
dThdPase expression, 1619
orthotopic model, SCID mice, 879
plasma K-ras mutations, 1527
Pancreatic carcinoma
orthotopic model, SCID mice, 879
p21 expression, 1147
plasma K-ras mutations, 271
Papillary thyroid carcinoma
RET/NEK1 rearrangements, 223
RET/PTC activation, 287
Parathyroid nodules
genetic abnormalities, uremia, 211
Pediatric leukemia
acute
cranial irradiation and BBB
permeability to ara-C, 69
antifolate ex vivo activity, 2399
relapsed
combination fludarabine and ara-C
infusions pharmacology, 45
Pediatric leukemia, acute lymphoblastic
B-progenitor cell
MTXPGs and and chromosome
12p11-13 translocations, 183
RFC expression, 2169
Pediatric solid tumors
refractory
toptocean infusion, phase II trial, 357
Pegylated (STEALTH) liposomes
-encapsulated GL14721C
pharmacokinetics and antitumor
activity, HT29 colon tumor
xenografts, 3077
Pelvic carcinoma
dendritic cells, 799
Peptides
DOTA-peptide-Chl6
carcinoma xenografts, 2483
HER-2/neu-associated
proliferative responses, breast cancer,
2015
Perillyl alcohol
daily, phase I trial, 1159
Peripheral blood
tumor, CEA mRNA
quantitative analysis, pancreatic ductal
adenocarcinoma, 855
mononuclear cells
AGT heterogeneity, 475
Ph+ myeloid cells, chronic
myelogenous leukemia, 861
progenitor cells
mobilization factors, lymphoma, 311
stem cells
transplantation, dendritic cell-based
tumor vaccines and, 2709
tumor cells
detection by RT-PCR, 2141
detection by RT-PCR for EGFR,
carcinoma, 3037
tyrosinase mRNA, malignant melanoma,
419
P-glycoprotein
MDR1
expression and function, breast
cancer, 389
prognostic role, muscle-invasive
urothelial transitional cell carcinoma,
559
Phagocytosis
carcinoma invasion and, 507
Phenylbutyrate
growth inhibition and differentiation
enhancement, colon carcinoma, 2503
Phenotin
and topotecan clearance, medulloblastoma, 783

**Philadelphia chromosome**
acute lymphoblastic leukemia cells tyrosine kinase inhibitors, 1661
myeloid cells peripheral blood, chronic myelogenous leukemia, 861

**Photodynamic therapy**
natural animal tumors, 2207
Np6, cutaneous disease, 2741

**Pituitary tumors**
chromosome 11q13 allelic loss, MEN 1, 1673

**Plasma**
K-ras mutations pancreatic adenocarcinoma, 1527
pancreatic cancer, 271

**Plasminogen**
activation system expression, kidney cancer, 869

**Plasminogen activator inhibitor**
type-1 levels, node-negative breast cancer, 177

**Platelet-derived endothelial cell growth factor**
expression, oral and oropharyngeal carcinoma, 1583
gastric cancer angiogenesis, 429
tumor chemosensitivity and, 2371
cis-Platinum combined with 5-fluorouracil biomarkers and, gastric cancer, 1469
PNU 152241: see Talimustine PNU 214565 phase I repeat dose, advanced gastrointestinal malignancies, 1903

**POH:** see Perillyl alcohol

**Polymerase chain reaction**
enriched oncogene hot spot detection, lung cancer, 361
germ cell tumor cells in apheresis products, 93
quantitative assay p16 copy number change detection, bladder tumors, 441
quantitative reverse transcription MDR1 and MRP expression, breast carcinoma, 1533
reverse transcription peripheral blood tumor cells, 2141
reverse transcription, EGFR peripheral blood cancer cell detection, breast carcinoma, 3037

**Polynucleotide immunization**
avgain carcinobryonic antigen, 2903

**Portal blood**
CEA mRNA quantitative analysis, pancreatic ductal adenocarcinoma, 855

**Positron emission tomography**
boron neutron capture therapy with L-\(^{10}\)B-BPA, glioma, 1825, 1833
[F-18]fluorodeoxyglucose quantitative, sarcoma, 1215

**Preneoplasia**
bronchial immunohistochemistry, 1609

**Progenitor cells**
peripheral blood mobilization factors, lymphoma, 311

**Progesterone receptors**
ovarian carcinoma, 2245

**Prostate adenocarcinoma**
growth inhibition by CEP-751, 1887
homozygous PTEN deletions, 811
prognostic transcription factors, 2153

**Prostate carcinoma**
Bone Scan Index, 1765
caveolin expression, 1873
combination Ad-mediated p53 gene therapy and paclitaxel, 835
combination radiation and ibuprofen therapy antitumor effects, 763
combination suramin and aminogluthethimide treatment, 37
combined suramin and doxorubicin treatment, 1193
comparative genomic hybridization, African-Americans and Caucasian Americans, 1273
doxorubicin pharmacodynamics, 277
drug resistance genes, 1393
early-stage versican levels, 963
estramustine uptake, 2079
Fas ligand secretion, 1803
IL-10 antimitastatic and antitumor activities, 2257
immunotherapy target antigens, 295
metastases inhibition by targeted IL-2, 2551
PSA mRNA expression, 2187
PTEN deletions, homozygous, 811
sequential IFN-γ and MAB CC49 therapy, 643
systemic IL-2 therapy, 2009
TGF-β receptor expression, 1625
TNF and cachexia, 1743

**Prostate cells**
circulating neoadjuvant hormonal therapy effects, 2119

**Prostate-specific antigen**
mRNA expression, prostate carcinoma, 2187
prognostic value, breast cancer, 1489

**Protein antigens**
selection for immune attack, 2669

**Protein kinase A**
type I EGFR interactions, 821

**Protein kinase C α**
expression, glioma, 1797

**Proteins**
apoptosis-regulating combination therapy outcome and, esophageal squamous cell carcinoma, 2991

**Proto-oncogenes:** see specific genes

**Pseudomonas exotoxin**
heregulin fusion proteins, recombinant, 993

**PTC**
activation, papillary thyroid carcinoma, 287

**PTEN/MMAC1 gene deletions**
glioma, 2447

**Rabbit liver carboxylesterase**
APC conversion to SN-38, 3089

**Radiation**
cranial and BBB permeability to ara-C, pediatric acute leukemia, 69
γ-radiation survival and mutagen sensitivity, glioma, 3031
lung cancer cytokinesis-block assay, 677

**Radiochemotherapy**
combined with surgery apoptosis-regulating proteins and, esophageal squamous cell carcinoma, 2991

**Radioimmunoassay**
LY309887, 157

**Radioimmunotherapy**
131-I-G250, metastatic renal cell carcinoma, 2729

**Radiosensitization**
IUDR-mediated IPdR prodrg, mouse and human tissues, 99

**Radiotherapy**
combined with ibuprofen antitumor effects, prostate carcinoma cells, 763
combined with IL-2, metastatic renal cell carcinoma, 283
combined with paclitaxel phase II trial, non-small cell lung cancer, 1931

**Raf-1 kinase**
activity paclitaxel cytotoxicity and, 1111

**Raltitrexed**
synergy with irinotecan, colon cancer cells, 1323

**Receptors**
see specific receptors

**Red blood cells**

**homozygous, prostate adenocarcinoma, 811**
mutations, endometrial carcinoma, 3005
synchronous endometrial and ovarian carcinoma, 2577

**Pyrazine dihydroxide**
phase II studies, advanced renal and colorectal cancer, 929

**Pyrazoloacridine and DNA topoisomerases I and II, 683**

**Pyridoxine**
and Doxil-induced cutaneous toxicity, 1567

**Quinones**
antitumor NQO1-directed, screening system, 3083

**Quinones**

**Quinones**
antitumor NQO1-directed, screening system, 3083

**Rabbit liver carboxylesterase**
APC conversion to SN-38, 3089

**Radiation**
cranial and BBB permeability to ara-C, pediatric acute leukemia, 69
γ-radiation survival and mutagen sensitivity, glioma, 3031
lung cancer cytokinesis-block assay, 677

**Radiochemotherapy**
combined with surgery apoptosis-regulating proteins and, esophageal squamous cell carcinoma, 2991

**Radioimmunoassay**
LY309887, 157

**Radioimmunotherapy**
131-I-G250, metastatic renal cell carcinoma, 2729

**Radiosensitization**
IUDR-mediated IPdR prodrg, mouse and human tissues, 99

**Radiotherapy**
combined with ibuprofen antitumor effects, prostate carcinoma cells, 763
combined with IL-2, metastatic renal cell carcinoma, 283
combined with paclitaxel phase II trial, non-small cell lung cancer, 1931

**Raf-1 kinase**
activity paclitaxel cytotoxicity and, 1111

**Raltitrexed**
synergy with irinotecan, colon cancer cells, 1323

**Receptors**
see specific receptors

**Red blood cells**
lometrexol pharmacokinetics, 2349

**Reduced folate carrier**

RFC gene
expression, childhood acute lymphoblastic leukemia, 2169

**Renal cell carcinoma**
advanced
PZDH, phase II studies, 929
subcutaneous RHU1-L12 treatment, 1183
T-cell signal transduction abnormalities, 2337
dendritic cell recruitment and activation, 585
growth inhibition
anti-EGFR mAb C225, xenografts, 2957
metastatic
131-I-G250 radioimmunotherapy, 2729
sequential radiation and IL-2 treatment, 283
multifocal
loss of heterozygosity, 2491
plasminogen activation system expression, 869
prognosis
lymph-in-6 and, 2419
telomerase activity, 197
tumor angiogenesis and chemotherapy, models, 1331

**Restriction fragment length polymorphism**

enriched PCR
 oncogene hot spot detection, lung cancer, 361

**Retinoblastoma protein**
bladder cancer progression, 829
expression and prognosis, acute myelogenous leukemia, 1955

**Retinoic acid**
8-Ci-cAMP synergy
apoptosis induction, CHP-100 cells, 755

9-cis-Retinoic acid
phase I study, advanced cancer, 1437

all-trans Retinoic acid
apoptosis induction, non-small-cell lung cancer, 1345
combined with tamoxifen, advanced breast cancer, 635

**RET/PTK1**
arraangements, papillary thyroid tumors, 223

**RET/PTC**
activation, papillary thyroid carcinoma, 287

**Retrovirus**
sequences expression, breast carcinoma, 2565

**RH1**
NQO1-directed antitumor agent, 3083

**Rhabdomyosarcoma**
drug sensitization and wtp53
overexpression, 145
intermittent topotecan exposure efficacy, xenografts, 1995

**RHAMM:** see **Receptor for hyaluronan-mediated motility**

**Ribonucleoprotein A2/B1**
heterogeneous nuclear expression, chronic smokers, 1631

**Ricin**
anti-B4-blocked ricin
phase II bolus, relapsed B-cell non-Hodgkin’s lymphoma, 2599

**Ricin A chain immunotoxins**
anti-p185-RTA combined with anti-EGFR-RTA, cytoxocity, 2545

Ro 25-6766: see **1o,25-Dihydroxy-16-ene-23yne-26,27-hexafluoro-19-norcholesterol**

**Rosenthal Foundation, Richard and Hinda**
Twenty-first Award Lecture, 1079

**S**

**Sarcoma**
Ewing’s
apoptosis induction by 8-Ci-cAMP and retinoic acid synergy, CHP-100 cells, 755
CD40 expression, 1843
osteosarcoma
CD40 expression, 1843
TP3-PAP antitumor activity, xenograft models, 1641
Y-B-1 nuclear expression, 2273
quantitative FDG PET, 1215
rhodomyosarcoma
drug sensitization and wtp53 overexpression, 145
intermittent topotecan exposure efficacy, xenografts, 1995
soft-tissue
Cdk4 overexpression, 1065
p16/MTS1 mutations, 1065
p53 restoration, 1985
soft-tissue, extremity
cyclin D1 and prognosis, 2377
soft tissue liposarcoma
**FUS-CHOP** fusion transcripts, 1779
telomerase activity and p53 status, 1573

**Secreted protein acidic and rich in cysteine**
overexpression, esophageal carcinoma, 1375

**E-Selectin**
soluble
circulating, breast cancer, 373

**Serum**
anti-p53 antibodies, lung carcinoma, 3025
carcinogenic embryonic antigen, colorectal cancer, 1511
cathepsin B, colorectal cancer, 1511
Epstein-Barr virus DNA, nasopharyngeal carcinoma, 665
tumor markers
marinismut and, 1101
tumor necrosis factor and cachexia, prostate cancer, 1743
vascular endothelial growth factor preoperative, colorectal cancer staging, 1279

**Severe combined immunodeficiency**
orthotopic pancreatic adenocarcinoma model, mice, 879
TP3-PAP antitumor activity, mouse osteosarcoma xenograft models, 1641

**Signal transducer and activator of transcription proteins**
activation by IFN-α, malignant melanoma, 2219

**Silymarin**
anticarcinogenic effects, breast cancer cells, 1055
Smokers
hnRNP A2/B1 expression, 1631
SN-38: see **7-Ethyl-10-Hydroxycamptothecin**

**Soft tissue liposarcoma**
**FUS-CHOP** fusion transcripts, 1779

**Soft-tissue sarcoma**
Cdk4 overexpression, 1065
extremity
cyclin D1 and prognosis, 2377
p16/MTS1 mutations, 1065
p53 restoration, 1985

**Solid tumors**
advanced
combination acivicin and aminosyn, phase I study, 2763
titanocene dichloride, phase I study, 2701
intractable
combination capcetabine and leucovorin, phase I study, 2755
oral 9-aminocamptothecin capsule bioavailability, 1915
oral topotecan administration, 1153
pathobiology
paclitaxel activity and, 2949
refractory
topotecan infusion, pediatric phase II trial, 357
tributyrin, phase I study, 629

**Somatostatin receptors**
breast carcinoma, 2047

**Southwest Oncology Group**
tamoxifen response
hsp27 and hsp70 and, metastatic breast carcinoma, 1263

**SPARC:** see **Secreted protein acidic and rich in cysteine**

**Special lectures**
Twenty-first Richard and Hinda Rosenthal Foundation Lecture
anticancer drugs, 1079

**Spermidine/spermine N1-acyetyltransferase**
SSAF gene
active copies, and BESpm sensitivity, 2003

**SPI-355:** see **Pegylated (STEALTH) liposomes**

**Squamous cell carcinoma:** see **specific sites**

**Staphylococcal enterotoxin A**
Fab fusion protein PNU-214565, phase I repeat dose, 1903

**Stealth liposomes**
doxorubicin
cutaneous toxicity, pyridoxine and, 1567
GL147211C
pharmacokinetics and antitumor activity, HT29 colon tumor xenografts, 3077
**Stem cells**
- autologous hematopoietic support combined with high-dose ICE and etanidazole, 1443
- autologous transplantation posttransplant paclitaxel, 2717
- peripheral blood transplantation dendritic cell-based tumor vaccines and, 2709

**Stress**
- apoptosis inhibition K-Ras and, colon carcinoma cells, 2841

**Stromelysin-3**
- overexpression, esophageal carcinoma, 1375

**Suramin**
- combined with aminoglutethimide, prostate cancer, 37
- combined with doxorubicin, prostate cancer treatment, 1193
- phase I and pharmacokinetic trial, 1429

**Surgery**
- combined with radiochemotherapy apoptosis-regulating proteins and, esophageal squamous cell carcinoma, 2991

---

<table>
<thead>
<tr>
<th>T101</th>
<th>( ^{99mTc} ) labeled</th>
<th>phase I study, CD5+ lymphoma, 2691</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tamoxifen</strong></td>
<td>phase I trial, advanced cancer, 53</td>
<td></td>
</tr>
<tr>
<td><strong>Taxol</strong></td>
<td>capcitabine efficacy enhancement, 1013</td>
<td></td>
</tr>
<tr>
<td><strong>Taxotere</strong></td>
<td>capcitabine efficacy enhancement, 1013</td>
<td></td>
</tr>
<tr>
<td><strong>Tea</strong></td>
<td>capcitabine efficacy enhancement, 1013</td>
<td></td>
</tr>
<tr>
<td><strong>Telomerase</strong></td>
<td>chemotheraphy modulation, 153</td>
<td></td>
</tr>
</tbody>
</table>

**Telomerase activity**
- bladder cancer diagnosis, 1949
- bladder transitional cell carcinoma, 535
- inhibition by AZT, breast cancer, 693, 2569
- ovarian lesions, 399
- and p53 status, sarcoma cells and fibroblasts, 1573
- renal cell carcinoma, 197
- telomerase-negative breast cancer, 435
- thyroid lesions, 1965

**Telomerase reverse transcriptase**
- human expression, 2807

**Temperature**
- antitubulin agent interactions, 1563

**Tenascin**
- anti-tenasin mAb 81C6 mouse/human chimeric, stability, 2495

| \( 1,4,7,10 \)-Tetraazaacyclodecane- \( N_2N_2N_2N_2 \) tetracetacid (DOTA)-peptide-ChL6 | breast carcinoma xenografts, 2483 |

| \( 2\text{'-Tetrahydroythrofuryl}-5 \)-fluorouracil | combined with uracil comparison with i.v. 5-FU, 2085 |

**Thrombomodulin 2**
- expression, non-small cell lung cancer, 1785

**Thymidylate synthase**
- antifolate inhibitors
  - \( \text{ex vivo} \) activity, childhood leukemia cells, 2399
  - antisense, 2229
  - expression and recurrence, colon cancer, 1227
  - inhibition by UCN-01, 2201
- mRNA levels, disseminated colorectal cancer, 1243

**Thyroid carcinoma**
- IL-6 expression, 381
- papillary
  - RET/INTRK1 rearrangements, 223
  - RET/PTC activation, 287

**Thyroid lesions**
- telomerase activity, 1965

**Tin-117m Stannic diethylenetriaminepentaacetic acid**
- metastatic bone pain treatment, 61

**Tissue-type plasminogen activator**
- levels, node-negative breast cancer, 177

**Titanocene dichloride**
- phase I study, advanced solid tumors, 2701

**T lymphocytes**
- also Cytotoxic T lymphocytes
- graft-versus-leukemia reactivity
  - antagonistic systemic IL-2 effects, murine model, 2635
  - signal transduction abnormalities, advanced renal carcinoma, 2337
  - stimulation via vaccine-coupled bs ABs, 721

**Tomudex**
- FURA cytotoxicity and, colon carcinoma, 469

**Topotecan**
- clearance
  - phenytoin effects, medulloblastoma, 783

**Treatment**
- with etoposide, sequentially, 1459
- cytoxic exposure, neuraxis, 2537
- 72-hour infusion, pediatric phase II trial, 357
- intermittent exposure
  - efficacy, medulloblastoma and rhabdomyosarcoma xenografts, 1995
  - oral, solid tumors, 1153
- phase II window study, acute lymphoblastic leukemia, 2677
- sensitivity
  - apoptosis induction and, ovarian tumors, 261

**Toxicity**
- BESpm, small cell lung cancer, 1557
- cutaneous
  - Doxil-induced, pyridoxine and, 1567
  - 5-fluorouracil
    - dihydropyrimidine dehydrogenase gene mutations and, 2999

**TP53 gene**
- mutations and colorectal cancer, 203

**TP3-pokeweed antiviral protein**
- antitumor activity, osteosarcoma xenograft models, 1641

**Transcription factors**
- E2F
  - combined with p53, gene transfer, 2265
  - prognostic for prostate adenocarcinoma, 2153

**Transforming growth factor \( \alpha \)**
- modulation
  - head and neck squamous cell carcinoma, 13

**Transforming growth factor \( \beta \) receptors**
- expression, prostate cancer, 1625

**Transforming growth factor \( \beta \)**
- expression and survival, non-small cell lung cancer, 1499

**Transitional cell carcinoma**
- bladder
  - complement factor H-like protein, 2511
  - telomerase activity, 535
  - urothelial, muscle-invasive
  - p53, metallothionein, Pgp, and MIB-1 prognostic role, 559

**Transplantation**
- autologous stem cell
  - posttransplant paclitaxel, advanced breast carcinoma, 2717
  - peripheral blood stem cell dendritic cell-based tumor vaccines and, 2709

**Trichothymin**
- phase I study, solid tumors, 629

**Trichosanthes japonica agglutinin-I**
- alkaline phosphatase binding, hepatocellular carcinoma, 2771

**Trimetrexate**
- high-dose
  - combined with minimal-dose leucovorin, 2981

**Trisomy 8**
- isolated, acute myeloid leukemia cytarabine-based chemotherapy, 1235

**Tumor antigens**
- selection for immune attack, 2669
<table>
<thead>
<tr>
<th>Subject</th>
<th>U266 cells</th>
<th>WHI-P131: 4-(4'-Hydroxyphenyl)-amino-6,7-dimethoxyquinazoline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor-associated antigen 22-1-1 expression, uterine cervical squamous</td>
<td>combination IL-6 with Taxol or vinblastine, 1039</td>
<td>WHI-P154: 4-(3'-Bromo-4'-hydroxyphenyl)-amino-6,7-</td>
</tr>
<tr>
<td>neoplasia, 1517</td>
<td></td>
<td>dimethoxyquinazoline</td>
</tr>
<tr>
<td>Tumor-associated glycoprotein-72 bispecific antibody lysis of cells</td>
<td></td>
<td>Wild-Type p53 expression, early operable non-small cell</td>
</tr>
<tr>
<td>expressing, 2237</td>
<td></td>
<td>lung cancer, 3017</td>
</tr>
<tr>
<td>Tumor colony-forming units oxaliplatin cytotoxicity, 1021</td>
<td></td>
<td>gene therapy, bystander effect, 2521</td>
</tr>
<tr>
<td>Tumor growth: see also Cell growth inhibition</td>
<td></td>
<td>multidrug sensitivity, 1315</td>
</tr>
<tr>
<td>CEP-751, prostate adenocarcinoma, 1887</td>
<td></td>
<td>overexpression</td>
</tr>
<tr>
<td>HuD vaccination, neuroblastoma, 2819</td>
<td></td>
<td>drug sensitization and,</td>
</tr>
<tr>
<td>IGF-IR mutant, 2647</td>
<td></td>
<td>rhabdomyosarcoma, 145</td>
</tr>
<tr>
<td>IL-10, prostate tumor cells, 2257</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor markers serum</td>
<td>marimastat and, 1101</td>
<td></td>
</tr>
<tr>
<td>marimastat and, 1101</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor necrosis factor and cachexia, prostate cancer, 1743</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumors: see also specific sites, types angio genesis and chemotherapy,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>and chemotherapy, renal cell carcinoma models, 1331</td>
<td></td>
<td></td>
</tr>
<tr>
<td>and growth factors, non-small-cell lung cancer, 241</td>
<td></td>
<td></td>
</tr>
<tr>
<td>apoptosis estramustine-induced, malignant glioma, 87</td>
<td></td>
<td></td>
</tr>
<tr>
<td>cisplatin sensitization by 6-aminoacetonicamide, 117</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cyd deaminase levels</td>
<td>DMDC activity and, 493</td>
<td></td>
</tr>
<tr>
<td>DMDM2-overexpressing therapy, 251</td>
<td>dissemination, colorectal cancer, 343</td>
<td></td>
</tr>
<tr>
<td>natural animal photodynamic therapy, 2207</td>
<td>MDM2-overexpressing models, 343</td>
<td></td>
</tr>
<tr>
<td>peripheral blood cells</td>
<td>RT-PCR detection, 2141</td>
<td></td>
</tr>
<tr>
<td>residual cells FUS-CHOP analysis, 1779</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor vaccines</td>
<td></td>
<td></td>
</tr>
<tr>
<td>dendritic cell-based</td>
<td></td>
<td></td>
</tr>
<tr>
<td>peripheral blood stem cell transplantation and, 2709</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tyrosinase mRNA</td>
<td>peripheral blood and bone marrow, malignant melanoma, 419</td>
<td></td>
</tr>
<tr>
<td>peripheral blood and bone marrow, malignant melanoma, 419</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tyrosine kinase inhibitors Ph-positive acute lymphoblastic leukemia, 1661</td>
<td></td>
<td></td>
</tr>
<tr>
<td>U266 cells combination IL-6 with Taxol or vinblastine, 1039</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UCN-01 thymidylate synthase inhibition, 2201</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ultraviolet B irradiation autologous melanoma cells combined with DETOX,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>metastatic melanoma, 619</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper gastrointestinal malignancies topoiso merase 1 inhibition</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pharmacodynamics, 545</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uracil combined with flotafur comparison with i.v. 5-FU, 2085</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uremia parathyroid nodule abnormalities, 211</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urine hTERT expression, bladder carcinoma, 2807</td>
<td></td>
<td></td>
</tr>
<tr>
<td>telomerase activity, bladder cancer diagnosis, 1949</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uroki nase system expression, kidney cancer, 869</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urokinase-type plasminogen activator levels, node-negative breast cancer, 177, 189</td>
<td></td>
<td></td>
</tr>
<tr>
<td>tumor-associated and prognosis, esophageal adenocarcinoma, 1755</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urothelial carcinoma telomerase subunit expression, 1603</td>
<td></td>
<td></td>
</tr>
<tr>
<td>transitional cell, muscle-invasive p53, metallothionein, Fpp, and MIB-1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>prognostic role, 559</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uterine cervical carcinoma squamous cell 22-1-1 Ag expression, 1517</td>
<td></td>
<td></td>
</tr>
<tr>
<td>cholesterol sulfate and cytokeratin coexpression, 2985</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaccination antican cer IL-2 liposomes, 1881</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HuD growth inhibition, neuroblastoma, 2819</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Id-pulsed dendritic cell multiple myeloma, 957</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaccines -coupled bs Abs T-cell stimulation, 721</td>
<td></td>
<td></td>
</tr>
<tr>
<td>dendritic cell-based</td>
<td></td>
<td></td>
</tr>
<tr>
<td>peripheral blood stem cell transplantation and, 2709</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV lipopeptide, cellular immune responses, 2103</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaginal carcinoma HPV lipopeptide vaccine response, 2103</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vascular endothelial growth factor esophageal carcinoma, 2195expression</td>
<td></td>
<td></td>
</tr>
<tr>
<td>early operable non-small cell lung cancer, 3017</td>
<td></td>
<td></td>
</tr>
<tr>
<td>lung adenocarcinoma, 1483 serum preoperative, colorectal cancer staging, 1279</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Versican levels, early-stage prostate cancer, 963</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vinblastine combined with IL-6, myeloma cells, 1039</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vinblastine combined with IL-6, myeloma cells, 1039</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vincristine and p53 function, 1047</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin D growth inhibitory effects, colon carcinoma xenografts, 2869</td>
<td></td>
<td></td>
</tr>
<tr>
<td>expression, colorectal cancer, 1591</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight loss circulating leptin levels and, gastrointestinal carcinoma, 2977</td>
<td></td>
<td></td>
</tr>
<tr>
<td>YB-1 protein nuclear expression, osteosarcoma, 2273</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yttrium-90 Yttrium-90-labeled T101 phase I study, CD5+ lymphoma, 2691</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZD1694: see Raltitrexed</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Instructions for Authors

Scope
Clinical Cancer Research, a journal of the American Association for Cancer Research, publishes original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Its focus is on innovative clinical research and translational research which bridges the laboratory and the clinic. Clinical Cancer Research is especially interested in clinical trials evaluating new treatments for cancer; research on molecular abnormalities that predict incidence, response to therapy, and outcome; and laboratory studies of new drugs and biological agents that will lead to clinical trials in patients.

Specific areas of interest include clinical and translational research in: molecular pharmacology and chemotherapy; drug sensitivity and resistance; tumor immunology and immunotherapy; radiobiology and radiation oncology; solid tumor oncology; hematological malignancies; surgical oncology; pediatric oncology; molecular oncology and cancer genetics; pathology, markers, and prognostic indicators; growth factors, cytokines, and signal transduction; bone marrow transplantation; gene therapy; cancer endocrinology; cell adhesion, invasion, and metastasis; prevention of primary and recurrent cancer; differentiation and cell death; clinical genetics; and detection of minimal disease.

Editorial Policy
When a manuscript is received for consideration, the Editors assume that no similar paper has been or will be submitted for publication elsewhere. Further, it is understood that all authors listed on a manuscript have agreed to its submission. The signature of the corresponding author on the letter of submission signifies that these conditions have been fulfilled.

Journal policy requires that authors, reviewers, Associate Editors, and Senior Editors reveal in a letter to the Editor-in-Chief any relationships that they have that could be construed as causing a conflict of interest with regard to a manuscript under review. The letter should include a statement of any financial relationships with commercial companies involved with a product under study.

Upon acceptance, authors must transfer copyright to the American Association for Cancer Research, Inc., the copyright owner of the journal, prior to publication. Once an article is accepted for publication in Clinical Cancer Research, the information therein is embargoed from reporting by the media until the mail date of the issue in which the article appears.

The Editors endorse the principles embodied in the Declaration of Helsinki and expect that all investigations involving humans will have been performed in accordance with these principles. To obtain a copy of the Helsinki Declaration, please contact the World Medical Association, 28, Ave. des Alpes, F-01210, Ferney-Voltaire, France. For animal experimentation reported in the journal, it is expected that investigators will have observed the Interdisciplinary Principles and Guidelines for the Use of Animals in Research, Testing, and Education issued by the New York Academy of Sciences’ Ad Hoc Committee on Animal Research, a copy of which is available for $5.00 from the Marketing Department, New York Academy of Sciences, 2 East 63rd Street, New York, NY 10021-7289. All human and animal studies must have been approved by the investigator’s Institutional Review Board.

Review Process
The review process is conducted as rapidly as possible. Each submitted manuscript is reviewed by at least two experts in the field of investigation. If the authors are invited to submit a revised manuscript for an expedited further review, the revised version must be submitted within three months.

Publication Fees
A page charge of $50 per printed page will be levied on all manuscripts accepted for publication. It is understood at the time of submission that the author(s) agree to pay this charge in the event of publication. Under exceptional circumstances, when no grant or other source of support exists, the author(s) may apply to Dr. Margaret Foti, Director of Publications, AACR Publications Department (see page ii for address) at the time of submission for a waiver of the page charges. All such applications must be countersigned by an appropriate institutional official stating that no funds are available for the payment of page charges.

Procedures for Submission
Submit papers directly to the Deputy Editor or to one of the seven Senior Editors, each of whom is responsible for a particular area of research. The Deputy Editor and the Senior Editors will conduct the review process with the expert assistance of the journal’s Associate Editors, who will correspond with authors about their manuscripts, and will make editorial decisions regarding publication. Papers within the subject areas covered by the Editor-in-Chief, as well as manuscripts that do not pertain to any of the research areas listed, should be submitted to Dr. Mendelsohn. Research areas, mailing addresses, and telephone and fax numbers for the Editor-in-Chief, Deputy Editor, and Senior Editors can be found at the end of these Instructions.

Submit four original sets (not photocopies) of figures along with four copies of the manuscript. If a manuscript is closely related to papers that are in press or have been submitted to another journal, please provide copies of those papers with your submission. For both original and revised submissions, we cannot guarantee that manuscripts and illustrations will be returned to the author.

The letter of submission can suggest the Associate Editors who might serve as reviewers of the manuscript. In addition, we invite authors to provide the names, addresses, and telephone/fax numbers of other potential reviewers who are not current or recent collaborators or advisors in the area under investigation.

Advances in Brief will be reserved for concise, definitive reports of novel observations and discoveries that have unusual importance. A request for consideration for Advances in Brief should be included in the letter of submission. A Minireview is a brief analysis (typically 3-4 printed pages) of a focused, timely research topic, aimed at a multidisciplinary audience. Minireviews and Controversies in Clinical Cancer Research that are submitted or solicited will undergo editorial review. The Editors welcome Letters to the Editor, which will be published if they are determined to be appropriate.

Format
Manuscripts must be written succinctly in clear, grammatical English. Define abbreviations in an inclusive footnote to the text. Double-space on 8 1/2 x 11-inch paper. Dot-matrix printing is not acceptable. The format is as follows:

1. Title page, including title, authors and their institutions, research support, and address plus telephone/fax numbers of the corresponding author;
2. A running title of fewer than 50 characters;
3. Three to five key words that do not appear in the title;
4. Abstract, of not more than 250 words, stating briefly the objectives, methods, results, and conclusions of the study;
5. Text arranged in this order: Introduction, Methods, Results, Discussion, Acknowledgments, References;
6. Footnotes, on a page separate from the text. Designate footnotes consecutively with superscript Arabic numerals;
7. Tables, on pages separate from the text, with descriptive titles and legends that make the data understandable without reference to the text;
8. Figure legends, on pages separate from the text, with descriptive titles and explanations to make the data understandable without reference to the text. Define all symbols and include staining for halftones where applicable;

References
Include only those articles that have been published or are in press. Unpublished data or personal communications must be cited as footnotes to the text. Personal communications should be substantiated by a letter of permission. Number references in the order of their first mention in the text. Cite only the number assigned to the reference. References must be double-spaced.
SAMPLE REFERENCES:

Figures
Provide four original sets of figures (whether line-cut drawings or halftones). Each sorted set should be in a separate labeled envelope, for distribution to reviewers. A typed label placed on the reverse side of each figure should contain the first author’s name, figure number, and an arrow indicating top of figure. Letters and numbers on figures should not be smaller than 6-point or larger than 12-point type. All figures will be published at a width of approximately 3 inches (8 cm) unless the author requests a greater width. Use tissue overlays to indicate important areas of the photographs that must be reproduced with greater fidelity.

Authors are encouraged to submit color figures. The expense of reproducing color photographs must be offset partially by the author. The cost of color reproduction charged to authors is $975 per color figure. Submit color figures on flexible backing.

Proofs
Page proofs must be returned to the office of the American Association for Cancer Research within 24 hours of receipt. Return proofs by overnight mail. Proofs not received by the deadline will be published without the authors’ corrections. Accepted manuscripts are regarded as final copy and should not be altered substantially in proof. Extensive alterations could cause publication delays, and authors will be charged for excessive alterations in proof.

Typesetting Manuscripts from Computer Disks
Clinical Cancer Research requests the submission of disks to expedite production of accepted manuscripts. If your article is accepted for publication, you will receive instructions regarding disk submission. It is the author’s responsibility to ensure that the material on the disk matches the final accepted version of the manuscript.

Research Areas of the Editor-in-Chief, Deputy Editor, and Senior Editors
John Mendelsohn, M.D., Editor-in-Chief
Department of Publications—227
The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Boulevard
Houston, TX 77030
Phone: (713) 792-6014; Fax: (713) 792-6016
E-mail: jmendelsohn@notes.mdacc.tmc.edu

Growth factors, hormones, cell growth, radiation therapy, surgery, subspecialty investigation

Waun Ki Hong, M.D., Deputy Editor
Department of Thoracic/Head & Neck Medical Oncology
The University of Texas M. D. Anderson Cancer Center
Box 80
1515 Holcombe Boulevard
Houston, TX 77030
Phone: (713) 792-6363; Fax: (713) 796-8655
E-mail: waun_hong@isqmd.uth.tmc.edu

Clinical trials targeted at specific malignancies, chemoprevention

Bruce A. Chabner, M.D.
Department of Hematology/Oncology
Massachusetts General Hospital
Cox Building, Room 640
100 Blossom Street
Boston, MA 02114

Phone: (617) 724-3200; Fax: (617) 724-3166
E-mail: chabner.bruce@mgh.harvard.edu

Clinical pharmacology and pharmacokinetics, drug metabolism, drug sensitivity and resistance, drug interactions

Michael B. Kastan, M.D., Ph.D.
Department of Hematology-Oncology
St. Jude Children’s Research Hospital
332 N. Lauderdale St.
Memphis, TN 38105-2794
Phone: (901) 495-3968; Fax: (901) 495-3966
E-mail: michael.kastan@sjude.org

Cell cycle regulation, cell death

Lance A. Liotta, M.D., Ph.D.
Laboratory of Pathology
National Cancer Institute
Building 10, Room 2A33
National Institutes of Health
10 Center Drive, MSC 1500
Bethesda, MD 20892-1500
Phone: (301) 496-3185; Fax: (301) 402-0043
E-mail: lance@helix.nih.gov

Pathology, metastasis

David Sidransky, M.D.
Otolaryngology/Head & Neck Cancer Research
Johns Hopkins University
818 Ross Research Building
720 Rutland Avenue
Baltimore, MD 21205-2196
Phone: (410) 550-5153; Fax: (410) 614-1411
E-mail: dsidrans@welchlink.welch.jhu.edu

Molecular pathogenesis, molecular correlates

Paul Sondel, M.D., Ph.D.
Departments of Pediatrics, Human Oncology, & Genetics
University of Wisconsin Clinical Science Center
K4/448
600 Highland Avenue
Madison, WI 53792
Phone: (608) 263-9069; Fax: (608) 263-4226
E-mail: pmsondel@facstaff.wisc.edu

Immunotherapy and cytokines—preclinical, and clinical trials

Beverly A. Teicher, Ph.D.
Lilly Research Laboratories
Lilly Corporate Center, DC 0540
Indianapolis, IN 46285
Phone: (317) 276-2739; Fax: (317) 277-3652
E-mail: teicher-beverly_a@lilly.com

Experimental therapeutics, preclinical pharmacology, combined modality regimens, animal therapy models

Jeffrey M. Trent, Ph.D.
Laboratory of Cancer Genetics
National Center for Human Genome Research
National Institutes of Health
Building 49, Room 4A22
49 Convent Drive, MSC 4470
Bethesda, MD 20892-4470
Phone: (301) 402-2023; Fax: (301) 402-2040
E-mail: jtrent@nchgr.nih.gov

Genetics, cytogenetics

For more information, contact:
John Mendelsohn, M.D., Editor-in-Chief, Clinical Cancer Research, Department of Scientific Publications—227, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: (713) 792-6014; Fax: (713) 792-6016 or:
Publications Department, American Association for Cancer Research, Public Ledger Building, Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483. Phone: (215) 440-9300; Fax: (215) 440-9355.
GUIDELINES FOR APPLICATION FOR ACTIVE AND CORRESPONDING MEMBERSHIP

BENEFITS OF MEMBERSHIP
The American Association for Cancer Research (AACR), a scientific society of over 13,500 laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage the presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

Members of the AACR enjoy the following benefits:
1. the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting;
2. subscriptions to the Association’s high-quality journals Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, and Cancer Epidemiology, Biomarkers & Prevention at reduced member rates;
3. an advance copy of the Program and Proceedings of the American Association for Cancer Research that contains over 4,000 abstracts of proffered papers presented at the annual meeting;
4. reduced registration rates at annual meetings;
5. priority notice of small, focussed meetings in the AACR’s exciting series of Special Conferences in Cancer Research;
6. substantially reduced registration rates for Special Conferences;
7. opportunities for participation in AACR meetings in North America and abroad with other scientific societies around the world;
8. receipt of AACR Newsletters and other important announcements;
9. early notification of and reduced rates for participation in the AACR Employment Register;
10. an up-to-date Membership Directory of over 13,500 member researchers in the cancer field;
11. the professional benefits of the AACR’s public education activities concerning funding for cancer research and press coverage of the latest research findings;
12. the opportunity to participate in three Summer Workshops that foster knowledge in the cancer field for young investigators;
13. the facilitation of informal scientific exchange with leading researchers in the cancer field; and
14. many more ongoing benefits.

QUALIFICATIONS FOR MEMBERSHIP
Active membership in the AACR is open to investigators who live in the Americas. Individuals who have conducted two years of research resulting in peer-reviewed publications relevant to cancer, or who have made substantial contributions to cancer research in an administrative or educational capacity, are eligible. If a candidate has conducted research in an area of biomedical science related to cancer, he or she will qualify for membership. Evidence of patents relevant to cancer research may be submitted as qualifications for membership in lieu of peer-reviewed publications.

Corresponding membership is open to persons who are not residents of the Americas. The qualifications for corresponding membership are the same as those indicated above for active membership. Visiting scientists from outside the Americas who intend to return to their countries of origin by the anticipated time of election should apply for corresponding membership. All other visiting scientists should apply for active membership and transfer to corresponding status upon leaving the Americas.

Graduate and medical students, postdoctoral fellows, and physicians in training who do not yet meet the above qualifications for active or corresponding membership should apply for associate membership. Forms for associate membership are available from the AACR Office.

PROCEDURES FOR APPLICATION
There are three deadlines for the receipt of a membership application: January 1, May 1, and September 1 of each year. The Membership Committee will review all complete applications for active membership that have been received by these deadlines and will submit recommendations on each candidate to the Board of Directors which formally elects all members. The same procedure is followed by the Special Memberships Committee which receives applications for corresponding membership. Candidates will be notified according to the following schedule:

<table>
<thead>
<tr>
<th>Receipt of Application</th>
<th>Notification of Candidate</th>
</tr>
</thead>
<tbody>
<tr>
<td>in AACR Office</td>
<td></td>
</tr>
<tr>
<td>January 1</td>
<td>March</td>
</tr>
<tr>
<td>May 1</td>
<td>July</td>
</tr>
<tr>
<td>September 1</td>
<td>November</td>
</tr>
</tbody>
</table>

A complete application consists of the following material:
1. 6 copies of the form on the opposite side of this page, with all requested information provided.
2. 5 copies of the candidate’s most current curriculum vitae and bibliography.
3. 5 copies of a letter of recommendation from a nominator who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). This letter should describe the candidate’s achievements in laboratory research, clinical investigations, or epidemiological research, and it should affirm that this research adheres to accepted ethical scientific standards. –OR– The nominator may supply the responses requested at the bottom of the application form in the section entitled “STATEMENT OF SUPPORT” (at least one copy of the form must be the signed original).
4. 5 copies of a letter of recommendation as described in Item 3 above from a seconder who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). –OR– The seconder may supply the responses requested at the bottom of the application form in the section entitled “STATEMENT OF SUPPORT” (at least one copy of the form must be the signed original).
5. 5 reprints of each of two publications on which the candidate appears as author. As noted above, evidence of patents developed by the candidate may be submitted in lieu of one or both of the publications. If submitting patents, supply patent number and year awarded.

All material should be collated into five complete sets with the original application form as a covering document and sent to the address given below. Questions regarding procedures for membership application may also be directed to the following address:

Membership Services Department
American Association for Cancer Research
Public Ledger Building, Suite 826
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Phone: 215/440-9300
Fax: 215/440-9412
E-mail: membership@aacr.org

RESPONSIBILITIES OF MEMBERSHIP
Candidates should be aware of the following responsibilities of membership in the AACR. Active members must pay annual dues. In 1999 annual dues for active members are $185, $105 of which is designated for AACR journal subscriptions. Newly elected members of the AACR who have already purchased subscriptions to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at the higher, nonmember rates will receive reimbursement of the unused portion of those subscriptions once their first year’s membership dues are paid in full.

Corresponding members are required to pay dues ($105 in 1999) and may, if they wish, subscribe to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at reduced member rates.

Applicants elected in March will be responsible for payment of that year’s dues; applicants elected in July and November will pay dues for the following year. Applicants elected in March and July will be eligible to sponsor an abstract for the next annual meeting. Every effort will be made to afford the same opportunity to applicants elected in November.

Margaret Foti, Ph.D.
Executive Director
APPLICATION FOR ACTIVE OR CORRESPONDING MEMBERSHIP

NAME OF CANDIDATE:_________________ LAST  FIRST  M.I.  DATE OF BIRTH:_________________  Month/Day/Year

PRESENT POSITION/TITLE:______________________________________________________________________________

INSTITUTIONAL AFFILIATION:__________________________________________________________________________

INSTITUTIONAL ADDRESS:____________________________________________________________________________

(City)  (State/Province)  (Country)  (Postal Code)

TELEPHONE NUMBER:_________________________  FAX NUMBER:________________________

E-MAIL ADDRESS:____________________________________________________________________________________

PRIMARY FIELD OF RESEARCH (Please check only one):

Biochemistry and Biophysics  Biostatistics  Carcinogenesis

Cellular Biology and Genetics  Clinical Investigations  Endocrinology

Epidemiology  Immunology  Molecular Biology and Genetics

Preclinical Pharmacology and Experimental Therapeutics

Other:__________________________________  (Please specify)

ACADEMIC DEGREES (Including where and when granted)

__________________________________________________________________________________________

__________________________________________________________________________________________

EXPERIENCE SINCE HIGHEST DEGREE WAS GRANTED (Please list most recent first)

__________________________________________________________________________________________

__________________________________________________________________________________________

PUBLICATIONS (Reprints of two peer-reviewed articles on which the candidate appears as an author must accompany this application. For these two articles list the authors, title, journal, volume, inclusive pages, and year. Do not submit abstracts. If submitting patents, supply patent number and year awarded.)

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

CANDIDATE IS APPLYING FOR (Check one):  □ ACTIVE  □ CORRESPONDING MEMBERSHIP

CANDIDATE NOMINATED BY*:__________________________________________

CANDIDATE SECONDED BY*:__________________________________________

( Please print)

( Please print)

STATEMENT OF SUPPORT

Instead of submitting letters of recommendation, either the nominator or the seconder or both may complete the following section:

I acknowledge by signing this statement of support that this candidate adheres to accepted ethical scientific standards and has or will make a long-term contribution to cancer research.

__________________________________________________________________________________________

Signature of Nominator*  Date  Signature of Seconder*  Date

See Guidelines for Application on the reverse side of this form for further instructions.

*Both nominator and seconder must be active, corresponding, emeritus, or honorary members of the AACR in good standing.

(This form may be reproduced.)
GUIDELINES FOR APPLICATION FOR ASSOCIATE MEMBERSHIP

QUALIFICATIONS FOR MEMBERSHIP

Associate membership is open to graduate students, medical students, postdoctoral fellows, and physicians in training who are following a course of study or who are working in a research program relevant to cancer. Scientists in training who already have a substantial record of publications may wish to apply for active or corresponding membership which confers full benefits of membership.

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society consisting of laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world. Associate members of the AACR enjoy the following benefits:

1. the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting provided that (a) the associate member is the presenter of the paper and (b) an active, corresponding, emeritus, or honorary member in good standing of the AACR also signs the abstract of the paper in support of the work. (In this instance, the member who cosigns the abstract does not lose his or her own sponsorship privilege);
2. optional subscriptions to the Association’s high-quality journals: Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, and Cancer Epidemiology, Biomarkers & Prevention at reduced member rates; beginning in 1998 associate members will be able to purchase AACR journals for half the price of a regular member subscription;
3. the privilege of registering for the annual meeting at the low associate member rate;
4. the privilege of electing an Associate Member Council that organizes programs benefiting associate members and that presents their concerns to the AACR Board of Directors;
5. the opportunity to stand for election to the Associate Member Council;
6. preferred access to the AACR Employment Register;
7. priority notification of events in the AACR’s series of special conferences on timely subjects in the field;
8. substantially reduced registration rates at special conferences;
9. the receipt of AACR newsletters, meeting announcements, and an up-to-date Membership Directory;
10. the opportunity to participate in three Summer Workshops that foster knowledge in the cancer field for young investigators; and
11. the facilitation of informal scientific exchange with leading researchers in the cancer field.

PROCEDURES FOR APPLICATION

Persons wishing to apply for associate membership must use the official application form on the reverse side of these instructions. Each candidate for associate membership must be nominated by an active, corresponding, emeritus, or honorary member in good standing of the AACR. Three completed copies of the form should be submitted; at least one of these copies must carry the original signatures of both the candidate and the nominator. In addition, the candidate should submit one copy of his or her curriculum vitae. The application form may be submitted to the Association Office at any time.

After review of applications for associate membership, the Executive Director will notify candidates of their election or deferral within one month of the receipt of the application form. A check for one year’s dues payment must accompany the application. Dues for 1998 and 1999 are $55 for associate members residing in the Americas and $65 for residents of other countries. This fee will be refunded to any candidate deemed to be ineligible for associate membership. Checks should be in U.S. currency, made payable to AACR, Inc., and drawn on a U.S. bank. Send the three copies of the application form and the appropriate dues payment to:

Membership Services Department
American Association for Cancer Research
Public Ledger Building, Suite 826
130 S. Independence Mall West
Philadelphia, PA 19106-3483
Phone: 215/440-9300
Fax: 215/440-9412
E-mail: membership@aacr.org

RESPONSIBILITIES OF MEMBERSHIP

Associate members must pay annual dues in an amount to be determined by the AACR Board of Directors. Dues for 1999 have been set at $55 per year for residents of the Americas and $65 for residents of other countries. If an application is submitted by August 31, the accompanying dues payment will be credited to the current year. Candidates submitting applications between September 1 and December 31 may indicate whether they wish their dues payments credited to the current or forthcoming year. Candidates should be aware, however, that associate members may sponsor an abstract for the annual meeting only if their dues for the current year are paid. For example, an associate member submitting an abstract in November 1998 for the forthcoming annual meeting must have paid dues for 1998. Any newly elected associate members of the AACR who have already purchased subscriptions to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at the higher, nonmember rate will receive a refund for the unused portion of that subscription upon receipt of their payment for a member’s subscription.

Each Fall the AACR will send to current associate members an invoice for dues for the forthcoming year. Payment of this invoice must be accompanied by a statement signed by the associate member’s current registrar, dean, or department head, verifying the member’s current academic status. The Association’s By-Laws state that dues are payable for each year in advance by January 1 of the year to which they should be applied. An individual may be an associate member for a maximum of five years. Each year in which an individual pays dues will count as one full year of associate membership. Thus, an associate member who pays dues for 1999 may retain associate membership until December 31, 2003. The Board of Directors may terminate the membership of an associate member whose dues are in arrears for two years.

Margaret Foti, Ph.D.
Executive Director
AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.
Public Ledger Building • Suite 826 • 150 S. Independence Mall West • Philadelphia, PA 19106-3483

APPLICATION FOR ASSOCIATE MEMBERSHIP

NAME OF CANDIDATE: ___________________________ LAST ______ FIRST ______ M.I. ______ DATE OF BIRTH: __________ Month/Day/Year

INSTITUTIONAL AFFILIATION: __________________________________________________________

INSTITUTIONAL ADDRESS: ___________________________________________________________

(City) ___________________________ (State/Province) ___________________________ (Country) ___________________________ (Postal Code) ___________________________

TELEPHONE NUMBER: ___________________________ FAX NUMBER: ___________________________

E-MAIL ADDRESS: __________________________________________________________

PRESENT ACADEMIC STATUS/TITLE (Please check only one):

☐ Graduate Student ☐ Medical Student ☐ Physician in Training ☐ Postdoctoral Fellow

Gender: ☐ Male ☐ Female

PRIMARY FIELD OF RESEARCH (Please check only one):

☐ Biochemistry and Biophysics ☐ Biostatistics ☐ Carcinogenesis
☐ Cellular Biology and Genetics ☐ Clinical Investigations ☐ Endocrinology
☐ Epidemiology ☐ Immunology ☐ Molecular Biology and Genetics
☐ Preclinical Pharmacology and Experimental Therapeutics ☐ Virology ☐ Other: ___________________________

(Please specify)

ACADEMIC DEGREES (Please indicate degree(s) acquired to date along with the name of the academic institution and date of receipt. Provide information on degree currently being sought and the anticipated date of completion of this degree program.)

_______________________________________________________________________________

_______________________________________________________________________________

_______________________________________________________________________________

RELEVANT RESEARCH EXPERIENCE NOT RELATED TO COURSE WORK (Please list most recent first.)

_______________________________________________________________________________

_______________________________________________________________________________

_______________________________________________________________________________

PUBLICATIONS (List the authors, title, journal, volume, inclusive pages, and year of any article in a peer-reviewed journal on which the candidate appears as an author. Do not list abstracts. Continue on a separate sheet, if necessary.)

_______________________________________________________________________________

_______________________________________________________________________________

_______________________________________________________________________________

CANDIDATE NOMINATED BY*: _____________________________________________________

(Please print)

SIGNATURES

I hereby apply for associate membership in the American Association for Cancer Research. I have read the instructions on the reverse side of this form, and I understand the privileges and responsibilities of this class of membership. I certify that the statements on this application are true.

Signature of Candidate: ___________________________________________________________ Date: __________

I recommend this candidate for associate membership in the American Association for Cancer Research. To the best of my knowledge, the candidate is qualified for this class of membership, and the statements on this application are true.

Signature of Nominator*: ___________________________________________________________ Date: __________

Submit three copies of this form. At least one copy must contain the original signatures of the candidate and the nominator. In addition, submit one copy of your curriculum vitae. Enclose a check in U.S. funds, made payable to AACR, Inc., and drawn on a U.S. bank for one year’s dues. For 1998 and 1999, dues are $55 for associate members residing in the Americas and $65 for residents of other countries.

Check one of the following boxes only if this form is being submitted between September 1 and December 31:

☐ The enclosed dues payment should be applied to the current ☐ forthcoming calendar year.

(NOTE: If dues are applied to the forthcoming year, membership will take effect on January 1, but the candidate will not be eligible to sponsor an abstract for presentation at the annual meeting in March or April of that year.) See Guidelines for Application on the reverse side of this form for further instructions.

*Nominator must be active, corresponding, emeritus, or honorary member of the AACR in good standing.

(This form may be reproduced.)

1999
Guidelines for Submitting Disks to American Association for Cancer Research Publications

The word processing packages that we prefer are as follows:

MacWrite
Microsoft Word (DOS, Windows, and Macintosh)
WordPerfect (DOS, Windows, and Macintosh)
XyWrite (DOS and Windows)

Also acceptable:

Ability
AmiPro
Appleworks
ArborTeX
ArborText
ClarisWorks WP
CPT 8000
CTOS
Diablo
DisplayWrite
Duet
Einstein
Enable
EXP
Final Word
FullWrite
GemWord
IBM Writing Assistant
Interleaf
LaTeX
Latex
Leading Edge
Lotus Manuscript
Lotus Write
Mass 11
MS Windows Write
MS Works
MS Works WP Mac
Multimate
Multimate Advantage
Nibia
Nisus (to ASCII file)
Notewriter
Obun
OfficeWriter
PC Write
PFS First Choice
Professional Write
Q&A Write
Quark XPress
RagTime MS Works
Rich Text Format
RSG (to ASCII file)
Signature
SLiTEx
SmartWhere
SmartWrite II
SoloWriter
Sprint
Stx
SunWrite
Symphony
TEX
TeX78
Text EXecutive
Textures
Total Word
Troff
μTeX
Volkswriter
VuWriter
Wang OIS
Wang WPS
Wang Writer
Window Works
Windows Write
WiziWord
Wordstar
Wordstar 2000
WriteNow
Xerox

Software packages that we are unable to translate:

FrameMaker
PageMaker
Ready, Set, Go
Scientific Writer

Disks produced on IBM or IBM-compatible computers are preferred, but those produced on some Apple or Wang computers can also be converted. Because of the file structures and internal coding, we cannot accept disks created on desktop publishing systems or those created on proprietary typesetting systems. We also cannot guarantee that all special characters can be translated. Tabular and mathematical material, such as equations, will not be captured from the disk but will be rekeyed.

To expedite work and for your own security, we do require that you submit a hard copy printout of the disk file. The tables and equations will be keyed from this hard copy. We also need to know the name of the file to be converted, the type of hardware (e.g., IBM PC) on which the files were created, the operating system (e.g., DOS 3.3), and the version of the software (e.g., WordPerfect 5.1) used to create the file.

PLEASE FILL OUT ALL INFORMATION ON REVERSE SIDE AND SUBMIT THIS FORM WITH YOUR DISK. DISKS WILL NOT BE PROCESSED WITHOUT THIS INFORMATION.
DISK SUBMISSION FORM

AACR journals are now using personal computers to copyedit manuscripts accepted for publication. When submitting a revised manuscript, authors are encouraged to submit an electronic disk of the paper along with the required four hard copy printouts. Disks will ultimately be returned to the authors.

See reverse for the word processing packages that can be accepted.

File preparation

Please be sure that the file you send is the most recent version of the manuscript and that it matches the most recently submitted printed copy. The file should contain all the parts of the manuscript in one file. Mathematical and tabular material, however, will be processed in the traditional manner and may be excluded from the disk file.

Note: AACR does not assume responsibility for errors in conversion of customized software, newly released software, or special characters.

Please label the outside of the disk with the journal name, the first author’s name, a partial title of the manuscript, and the name of the computer file used to access the manuscript on disk. To process your disk efficiently, we need the following information. Please be sure to provide ALL the information.

Name used to access paper on disk: ____________________________________________
Name of computer used (e.g., IBM/PS2): _____________________________
Operating system and version (e.g., DOS 3.3): ____________________________
Word processing program and version (e.g., WordPerfect 5.0): ______________________
[See reverse for acceptable programs.]

Manuscript number: ________________________________________________________
First author: __________________________________________________________________
Corresponding author (if different from first author): _____________________________
Telephone/FAX numbers: ______________________________________________________

This form (both sides) may be reproduced.
THE FEDERATION OF EUROPEAN CANCER SOCIETIES
THE AMERICAN ASSOCIATION FOR CANCER RESEARCH
THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

jointly organize

METHODS IN CLINICAL CANCER RESEARCH
An intensive workshop for European junior clinical oncologists of all disciplines to learn the essentials of clinical trials design

22 - 27 June 1999, Flims, Switzerland
Application Deadline: 15 February 1999

AIMS

• Introduce clinical oncologists in all disciplines to the principles of good clinical trials design.

• Expose clinical scientists to the full spectrum of challenges in clinical cancer research, including surgery, radiotherapy, conventional and investigational antineoplastics, gene therapy, biologic therapy and clinical prevention trials.

• Develop a cadre of well-trained, experienced researchers whose activity will promote better clinical trials design.

FACULTY

* Jean Pierre Armand, Institut Gustave Roussy, Villejuif, France
* Ian F. Tannock, Centre Léon Bérard, Lyon, France
* Daniel D. Von Hoff, Institute for Drug Development, San Antonio, USA
* Matti S. Aapro, Clinique de Genolier, Genolier, Switzerland
* Marie-Christine Bissery, Rhône-Poulenc Rorer, Vitry sur Seine, France
* George R. P. Blackledge, Zeneca Pharmaceuticals, Macclesfield, England
* Otis W. Brawley, National Cancer Institute, Bethesda, USA
* Gregory Burke, Novartis Pharma, Basel, Switzerland
* Marc Buyse, ID2, Brussels, Belgium
* Gary M. Clark, University of Texas Health Science Center, San Antonio, USA
* Charles A. Coltman, Jr., Cancer Therapy and Research Center, San Antonio, USA
* Ann Cull, Western General Hospital, Edinburgh, Scotland
* Ottilia Dalesio, Netherlands Cancer Institute, Amsterdam, The Netherlands
* Janice P. Dutcher, New York Medical College, Bronx, USA

** Alex M.M. Eggermont, University Hospital, Rotterdam, The Netherlands
** William Gullick, Hammersmith Hospital, London, England
* Catherine Hill, Institut Gustave Roussy, Villejuif, France
** Stanley B. Kaye, University of Glasgow, Glasgow, Scotland
** Margaret Kemeny, North Shore University Hospital, Manhasset, USA
** W. Gillies McKenna, University of Pennsylvania, Philadelphia, USA
** Max Parmar, MRC Cancer Trials Office, Cambridge, England
* Steven Piantadosi, Johns Hopkins Oncology Center, Baltimore, Maryland
** Ross Pinkerton, Royal Marsden NHS Trust, Sutton, England
* Eileen Rankin, Ninewells Hospital and Medical School, Dundee, Scotland
** Pierre Scalliet, UCL St.-Luc University Hospital, Brussels, Belgium
* Patrick Therasse, EORTC Data Center, Brussels, Belgium
* Martine van Glabbeke, EORTC Data Center, Brussels, Belgium
* Jacob Verweij, Rotterdam Cancer Institute, Rotterdam, The Netherlands
* Nu Viet Vu, University of Geneva, Geneva, Switzerland

*Program Committee Co-Chairpersons
**Program Committee Members

WORKSHOP SESSION FORMATS

The workshop scientific program will consist of three types of activities to serve a variety of didactic needs:

• Lectures will give participants a necessary overview of the field.

• Parallel discussion group sessions will enable participants to discuss specific items in a small session limited to 15 persons.

• During the protocol development sessions each participant will develop a concept sheet for a clinical trial protocol and, through extensive mentoring, design and complete the writing of the clinical trial protocol before the end of the workshop.

TOPICS

Lectures

New targets for cancer treatment
Basic biostatistics for the clinical trialist
Principles of clinical pharmacology
Phase III trials
Ethical issues raised in clinical trials
Radiotherapy in clinical trials
The design of clinical trials related to biological agents
The pitfalls of clinical trials
Design and conduct of Phase I clinical trials
Phase II trials
Regulatory affairs
Preclinical data for clinical trials
Chemoprevention and screening trials

Parallel discussion groups

New measures of outcome: quality of life, clinical benefit, cost benefit
Special problems in clinical trial design: cytostatic agents, angiogenesis inhibitors, growth factors
Special problems in design of clinical trials with biologics
Prognostic factors and screening
Special considerations for surgical oncology trials
The challenge of combined modality trials
Special considerations for radiation oncology trials
Statistics: statistical problems and the concept of meta-analysis

For information please contact the Workshop Secretariat
FECS, Avenue E. Mounier 83, B-1200 Brussels, Belgium
Tel. +32-2-7750202 • Fax +32-2-7750200

e-mail FECS: workshop@feecs.be • AACP: meetings@aacp.org • ASCO: asco@asco.org
National Cancer Institute Announces
cancerTrials™

http://cancertrials.nci.nih.gov

Featuring

Online

- The latest news in cancer research & trials
- Step-by-step guide to finding clinical trials
- Easy access to all clinical trials resources from NCI

Visit us at http://cancertrials.nci.nih.gov
AACR SPECIAL CONFERENCE IN CANCER RESEARCH

Cancer Biology and the Mutant Mouse: New Methods, New Models, New Insights

January 31-February 5, 1999
Keystone Resort & Conference Center
Keystone, Colorado

CONFERENCE CO-CHAIRPERSONS

Tyler Jacks / Cambridge, MA
Ronald A. DePinho / Boston, MA

CONFERENCE PROGRAM

Keynote Addresses
Richard D. Klausner / Bethesda, MD
J. Michael Bishop / San Francisco, CA

Model Systems I
Suzanne Cory / Melbourne, Australia
Tak W. Mak / Toronto, Ontario, Canada
Neal G. Copeland / Frederick, MD
Stanley J. Korsmeyer / St. Louis, MO
Pier Paolo Pandolfi / New York, NY

Genomics/Genetics
David E. Housman / Cambridge, MA
David H. Mack / S. San Francisco, CA
Allan Balmain / Richmond, CA
Peter Demant / Amsterdam, The Netherlands

Cancer Biology
Douglas Hanahan / San Francisco, CA
George D. Yancopoulos / Tarrytown, NY
Philip Leder / Boston, MA
Andrea I. McClatchey / Boston, MA

Applications
Jolene J. Windle / San Antonio, TX
Scott W. Lowe / Cold Spring Harbor, NY
Raymond W. Tennant / Res. Triangle Park, NC
Ronald A. Lubet / Bethesda, MD
Nancy Kohl / West Point, PA

Technologies
Joe W. Gray / San Francisco, CA
Anton Berns / Amsterdam, The Netherlands
Tetsuo Noda / Tokyo, Japan
Arthur Sands / The Woodlands, TX

Cancer Pathways
Martine F. Roussel / Memphis, TN
Guillermina Lozano / Houston, TX
Terry A. Van Dyke / Chapel Hill, NC
Erwin Wagner / Vienna, Austria
Nicole Schreiber-Agus / Bronx, NY

Special Lecture
Harold E. Varmus / Bethesda, MD

Model Systems II
Raju Kucherlapati / Bronx, NY
Glenn T. Merlino / Bethesda, MD
Timothy C. Thompson / Houston, TX

The conference will also feature a methods workshop session and a late-breaking research session.

Information and Registration Forms:

American Association for Cancer Research
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
E-mail: meetings@aacr.org
Website: http://www.aacr.org
Visit the AACR Website!

www.aacr.org

Turn to our website to find:

☐ AACR Scientific Meetings Schedule

☐ 1998 Annual Meeting Abstracts

☐ Abstracts of Articles from AACR Journals

☐ Instructions for Authors

☐ Information about AACR Research Fellowships and Young Investigator Awards

☐ The latest AACR Newsletter, and more!
AMERICAN ASSOCIATION FOR CANCER RESEARCH  
Research Grants for Young Cancer Scientists  

New! Application forms available on-line at http://www.aacr.org  

GERTRUDE B. ELION CANCER RESEARCH AWARD  
Supported by an Educational Grant from Glaxo Wellcome Oncology  

The Gertrude B. Elion Cancer Research Award is a one-year, $30,000 grant for a scientist in the U.S. or Canada engaged in meritorious basic, clinical, or translational research in cancer etiology, diagnosis, treatment, or prevention at the level of Assistant Professor (not yet tenured). The AACR will reimburse the Awardee for travel to the 1999 Annual Meeting in Philadelphia, PA, where Dr. Elion will personally present this Award.  

Eligibility/Selection Process  
Candidates must have completed postdoctoral studies or clinical fellowships not later than July 1 of the Award year, and ordinarily not more than five years earlier. Tenured faculty in academia, federal government employees, and employees of private industry are not eligible for this award. A Candidate need not be a member of the AACR at the time of application, but must be nominated by a Member of the AACR. Associate Members may not be nominators. Applications are evaluated by a Committee consisting of AACR Members who are experts in basic, clinical, translational, and prevention research. Application deadline: December 15, 1998.  

AACR RESEARCH FELLOWSHIPS  
For Young Scientists at the Postdoctoral or Clinical Fellow Level  
New! Some Two-Year Fellowships  

The AACR Research Fellowships in Clinical, Translational, Basic, and Prevention Research foster meritorious cancer research in North, Central, or South America by young scientists currently at the postdoctoral or clinical research fellow level. Sponsored by Amgen, Bristol-Myers Squibb Oncology, Cancer Research Foundation of America, the Sidney Kimmel Foundation for Cancer Research, AACR, and others, the AACR Fellowships provide either one or two years of salary support at the rate of $30,000 per annum. Those awarded two-year grants who receive a junior faculty appointment in the second year may use the funds for non-salary research expenses in connection with the new position.  

Eligibility/Selection Process  
Candidates must have completed the M.D., Ph.D., or other doctoral degree. Candidates must currently be a postdoctoral or clinical research fellow and must have been a fellow for at least two years but not more than five years prior to the year of the award. Academic faculty, graduate or medical students, medical residents, permanent government employees, employees of private industry, and individuals who will receive fellowships from similar programs during the award year are not eligible. A candidate need not be a member of the AACR at the time of application, but he or she must be nominated by an AACR Member, and non-members must submit an acceptable application for membership with the fellowship application. Associate Members may not be nominators. Applications are evaluated by a Committee consisting of AACR Members who are experts in basic, clinical, translational, and prevention research. Application deadline: January 15, 1999.  

For Further Information  
AMERICAN ASSOCIATION FOR CANCER RESEARCH  
Public Ledger Building, Suite 826  
150 South Independence Mall West  
Philadelphia, PA 19106-3483  
Telephone: (215) 440-9300  FAX: (215) 440-9372  E-mail: horst@aacr.org
AACR SPECIAL CONFERENCE IN CANCER RESEARCH

Molecular Determinants of Sensitivity To Antitumor Agents

March 4-8, 1999
Whistler Resort & Conference Centre
Whistler, British Columbia, Canada

CONFERENCE CO-CHAIRPERSONS
Michael B. Kastan / Memphis, TN
I. David Goldman / Bronx, NY

CONFERENCE PROGRAM

Keynote Address
Richard D. Klausner / Bethesda, MD

Tumor Physical Environment
Rakesh Jain / Boston, MA
Amato J. Giaccia / Stanford, CA
Robert S. Kerbel / Toronto, Canada
Valerie Weaver / Berkeley, CA

Transport/Cellular Pharmacology
I. David Goldman / Bronx, NY
Carol E. Cass / Edmonton, Canada
Michael M. Gottesman / Bethesda, MD

Drug-Target Interactions
Francis Ali-Osman / Houston, TX
James C. Wang / Cambridge, MA
Susan B. Horwitz / Bronx, NY
Thomas W. Griffin / Nutley, NJ

Responses to Specific Cytotoxic Agents
Josef Jiricny / Zurich, Switzerland
Isabel Mellon / Lexington, KY
Michael B. Kastan / Memphis, TN

Apoptosis I: Drug Responses
Scott H. Kaufmann / Rochester, MN
Janet A. Houghton / Memphis, TN
Kapil N. Bhalla / Atlanta, GA
Craig B. Thompson / Chicago, IL

Apoptosis II: Machinery/Signaling
Eileen White / Piscataway, NJ
Atul Bedi / Baltimore, MD
Avi Ashkenazi / S. San Francisco, CA

Apoptosis III: Targets
Peter J. Houghton / Memphis, TN
Renato Baserga / Philadelphia, PA
Tona M. Gilmer / Research Triangle Park, NC

Registration Deadline: January 4, 1999

Information and Registration Forms:
American Association for Cancer Research
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
E-mail: meetings@aacr.org
Website: http://www.aacr.org